



BIO CHINA | 2026 Fusion Forward International Convention

March 12-14, 2026 Suzhou International Expo Center

Strategic Ecosystem Partner
战略生态伙伴




Ecosystem Partner
生态伙伴



Platinum Sponsor
铂金赞助商



Gold Sponsor
黄金赞助商



✉ BIOCHINA@enmore.com

About BIOCHINA


BIOCHINA 2026 (11th) will be held from **March 12-14** at the Suzhou International Expo Center. Following the success of BIOCHINA 2025 (10th), which welcomed **30,000 attendees** in Suzhou, BIOCHINA continues its journey of boundless innovation and collaborative growth!

Over the past decade, BIOCHINA has **expanded from China's thriving biopharmaceutical sector to the world stage**, establishing an international platform for industry connectivity and uniting global expertise to advance collaboration.

Through technological breakthroughs, commercial implementation, capital support, and ecosystem integration, BIOCHINA has witnessed China's innovative drug industry evolve from following to leading, progressing alongside the industry and the times.

BIOCHINA2026 Fusion & Forward

'Fusion' embodies the power of an ecosystem, where diverse forces converge to unlock growth. 'Forward' represents future direction, pushing boundaries to define new heights for the industry. Standing at the threshold of a new decade, BIOCHINA 2026 will join hands with global partners to step into the next golden era of China's biopharmaceutical industry.



- 30000+** Attendees
- 400+** Exhibitors
- 850+** Speakers
- 40+** Countries

If you are interested in **Early-stage Research and Clinical Development**, you can click on each module to view more details:

New Clinical Models 【BD Post-Deal Clinical – IIT Models – AI in Clinical Trials】

Indication Development 【Cardiovascular – Kidney – Oncology – CNS – Metabolism – Ophthalmology – Autoimmune】

AI in Drug Development 【Target Discovery – Clinical Translation – R&D Efficiency】

Small Molecule Drugs 【Undruggable Targets – Molecular Glues – Oncology – Autoimmune – CNS】

Antibody Drugs 【Logic-Gated Technology – NKCE – MCE – PD1/VEGF Bispecifics – TCE – Tri-specifics – Combination Therapy】

ADC & XDC Drugs 【Dual-Payload ADC – Bispecific ADC – DAC – Bi-XDC – PDC – Computational Pathology – Autoimmune – Combination Therapy】

Radiopharmaceuticals 【Radionuclide Selection – Ligand Selection – Early Development – Clinical Indications】

Cell Therapy 【Synthetic NK Anti-Aging – Immunotherapy – CAR-T Solid Tumors – TCR-T Solid Tumors – CAR-NK Solid Tumors】

In-vivo CART 【LVV – LNP – Regulatory – Oncology – In vivo CAR-T – In vivo TCR-T – In vivo CAR Macrophage】

Stem Cell Therapies 【iPSC – MSC – Parkinson's Disease – Heart Failure – Ischemic Vascular Disease – Knee Osteoarthritis – Type 2 Diabetes – Acute Ischemic Stroke – Liver Cirrhosis – Liver Failure】

Regenerative Medicine 【Progenitor Cells – iPSC Regenerative Transplantation – Organoids – Tissue Engineering – Tissue Repair】

Gene Therapy 【Parkinson's Disease – Heart Failure – Oncology – Ophthalmology – Rare Diseases – Chronic Diseases】

Oligonucleotide Drugs 【Cardiovascular – Metabolism – Oncology – Hepatitis B – Lipid Reduction – Non-Hepatic Targets】

mRNA Drugs 【Cancer Vaccines – Fat-Targeting – Circular RNA – Base Editing】

Peptide Drugs 【Cyclic Peptides – Tri-Target – GLP-1 – Phase III Clinical Trials】

Exosome-Based Therapies 【Extracellular Vesicles – Engineered Exosomes – Delivery】

Biomanufacturing 【Cosmetic Ingredients – Novel Food Ingredients – Probiotics – Food & Medicine Homologs – Straw-Based – Microalgae Exosomes】

If you are interested in **process development and manufacturing quality**, you can click on each module to view more details:

CMC Global Expansion 【Regulations & Submissions in China, US, and EU – Pharmaceutical Registration & Variations – Technology Transfer & Compliant Manufacturing】

On-Site Inspections 【FDA/EMA/PICS Inspections – UAE Inspections – Colombia Audits – Data Integrity】

Global Regulatory 【Indonesia – Pakistan】

If you are interested in **process development and manufacturing quality**, you can click on each module to view more details:

Cell Line Development & Engineering 【High-Expression Cell Lines – Rapid Cell Line Development – CHO – Bioreactors】

Upstream & Downstream Process Development & Validation 【Digital & AI Technologies – Upstream Process – Robust Downstream Scale-Up – 10,000L Purification – Downstream Hierarchy – Downstream Process AI PSO Algorithms】

Formulation Development 【ADC Lyophilized Formulations – High-Concentration Antibody Formulations – Inhalation Formulations – Dual-Chamber Lyophilized Formulations – Long-Acting Peptide Formulations – Solid Dispersion Formulations – Aseptic Manufacturing】

Analytical Testing & Quality Management 【Updated Pharmacopeia – R&D Quality Management – Process Residue Control – Complex Molecule Quality Analysis – Characterization Analysis】

Peptide Synthesis 【Compound Formulations – Process Optimization – Production Optimization – Process Scale-Up】

Cell Therapy 【Future Manufacturing – Bedside Preparation – Fast CAR-T】

In vivo CART 【Vector Selection – Process Development – CMC】

AI in Process & Manufacturing 【Peptides – Nucleic Acid Drugs – Bispecific Antibodies – Fermentation】

Biomanufacturing 【New Fermentation Platforms – 10,000-Ton Industrial Fermentation – Enzyme & Metabolic Engineering – Cell Factories – Industrial Strains】

If you are interested in **BD deals and global markets**, you can click on each module to view more details:

BD Strategy 【MNC Asia-Pacific Strategy – Pharmaceutical Globalization – NewCo Evolution – Going Global – Payment Solutions】

Global Investment 【Investment & Financing Trends – LP-GP Ecosystem – Big Pharma Incubators – Industrial Investments – Hong Kong IPOs – China-US Taxation】

Finance, Tax & IP 【Financial & Tax Planning in Deals – Valuation – Global IP Strategy – Due Diligence – Risk Allocation】

International Markets 【Australia – Korea – India – Asia – Belt & Road – Russia – Middle East – Latin America】

Technology & Research Translation 【University Technology Transfer Models – Professor-Led Startups】

If you are interested in **procurement and supply chain**, you can click on each module to view more details:

Global Supply Chain 【Overseas Supply Chain – Europe & US Supply Chain – CGT Supply Chain – Large Molecule Supply Chain – CXO Supply Chain – Reagents & Consumables Procurement – Full-Category Supplier Management – Localization of Key Materials in Import Transfer Projects】

About the Exhibition

BIOCHINA 2026 (11th Edition) will feature six exhibition halls—**Laboratory Instruments, Pharma Equipment, Raw Materials & Reagents, Consumables, International Services, and General Services.** Onsite, participants can connect directly with domestic and international brands, engage with founders and senior technology executives, and enhance business cooperation efficiency between exhibitors, end users, and distribution partners.




BIO CHINA | 2026 Fusion Forward
International Convention

融合·领先 第十一届易贸生物产业展览

2026/03/12-14 SUZHOU·CHINA 中国·苏州


C3 International Service
国际服务馆




D3 Pharma Equipment & Laboratory Instruments
制药装备馆 & 实验室仪器馆



E3 Raw Materials & Reagents & Consumables
原料试剂 & 耗材馆



F3 General Services
综合馆



This image is not the final version of the booth layout
All rights of final interpretation belong to Enmore
此图非最终版展位图，最终解释权归易贸医疗所有

About the Conference

As a flagship event in China's biopharmaceutical industry, BIOCHINA is dedicated to promoting innovation and industrial translation in the sector. Centered on innovative drugs, the conference provides a comprehensive industry platform connecting research achievements, clinical needs, industrial application, and business development, fostering the exchange of cutting-edge technologies and best practices in industrialization.

In BIOCHINA 2025, the conference invited **74** chairs, Expert Committee Members, and Conference Producers and **850** speakers, creating **204** forums, **12** closed-door meetings, **25** brainstorming sessions, and initiating **10,000+** one-on-one BiOPartnering meetings.

BIOCHINA 2026 will continue to enhance both content and organization, **launching 20 inaugural forums. With industry tracks as the core focus, the conference will delve into specialized technologies, promote upstream and downstream industry collaboration, and bring together global experiences, driving efficient development of innovative drugs worldwide.**



About BiOPartnering

BiOPartnering offers **1-on-1, 30-minute meetings** to discuss cutting-edge technologies, innovative applications, and industry trends. Tailored to company needs, it facilitates investment, project deals, and strategic collaborations, promoting internationalization of the biotech industry and fostering global cooperation and win-win innovation.

BiOPartnering Partner



Partnering Room

1 Large Partnering Room



2 Large Partnering Room



3 Medium Partnering Room



4 Small Partnering Room



BIOCHINA2025	BIOCHINA2026 - Fully Upgraded
Participating companies 1,805	Participating companies 2,000+
Meetings arranged 2,679	Meetings arranged 3,000+
Participants from 28 countries and regions	Participants from 40+ countries and regions



BIOCHINA 2026 is expected to attract participants from **40+ countries and regions**, including key markets such as South Korea, Russia, the United States, and Singapore. Companies from **Asia, Europe, the Americas, and Oceania** will actively engage in collaborations with the Chinese market. A wide range of participation formats will be offered, including international forums, **the International Hall, 1-on-1 BiOPartnering meetings**, and **networking receptions**, providing a comprehensive platform for companies to explore new business opportunities.



Dr Reddy Inceptua Group Pfizer Inc. Canada India
Certest Pharma AbTis, Co., Ltd. Daewon Pharm. Co., Ltd.
Binnopharm Group Celltrion, Inc. Belgium Laboratorios Bago S.A.
USA Lilly Russia Torrent Pharma PROMOMED Germany
Spain 100+ senior executives from France
Novartis global pharmaceutical companies Sweden
Sun Pharma Find Projects Find Partnerships GeroPharma
GL PharmTech Daewoong Pharmaceutical Insud Pharma
Thailand Pakistan Singapore Bayer
United Kingdom Australia
Argentina Poland Korea
Pharmasyntez SENJU PHARMACEUTICAL

BIO CHINA | 2026 Fusion Forward
 融合·领先 第十一届易贸生物产业展览
 March 12-14, 2026 Suzhou International Expo Center

Registration


About BIOFestival

The First BIOFestival will take place from March 12–14 at the Suzhou International Expo Center, alongside BIOCHINA.

Under the theme “Life’s Light Shining with You,” the festival celebrates the people who bring biotechnology to life. Biotechnology is not just about laboratory data or manufacturing processes—it is about real lives, real health, and a shared future. It safeguards my health, my work, and my tomorrow.

The First BIOFestival focuses not only on breakthrough innovation, but also on the everyday dedication of scientists, engineers, and industry professionals. Each effort is a small light; together, they form a constellation that illuminates the future of human health. Key

Programs & Experiences include Talks on Life Sciences, Engaging Youth with Scientists, a Bacterial Culture Competition, Product Challenges & Playful Experiences, the Future of Life Networking Reception, and an IP Runway Show, offering a dynamic mix of science, creativity, and human connection. Experience Zones include the Charity Art Gallery, Tree of Life – Share Your Wishes, Your Year in Moments – Annual Visual Showcase, and the Share & Shine Interactive Space, creating an emotional bridge between science, life, and the people behind innovation. Where science meets emotion—and every light matters.



BIOCHINA 2026 (11th Edition) Agenda										
Mar12	Time	Room B3	Room C303	Hall C3 Roadshow	Room D304	Room D307	Room C302	Room C301	Room D305	Room D306
		Main Forum		Roadshow	International Forum	/	/	Radiopharmaceutical Innovation Forum	Global Supply Chain Innovation Forum	Innovative Process Technology Forum
	09:00-10:00	BIOCHINA2026 Opening Ceremony		Innovative Drugs	Australia Market	/	/	Future Exploration	/	Quality Analysis
	10:00-11:00					/	/		Opening Panel Discussion	
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BioBD Forum	Roadshow	Global Forum	Global Regulatory Forum	Global Core Therapeutic Areas Ecosystem Forum	Radiopharmaceutical Innovation Forum	Global Supply Chain Innovation Forum	Innovative Process Technology Forum
	12:00-13:00	Main Forum Interview	BD Strategy	Innovative Drugs	Korea Market	Regulatory Affairs – US & EU Markets	Cardiovascular & Renal Diseases	Innovative R&D	Global Supply Chain Development	Quality Analysis
	13:00-14:00									
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BioBD Forum	Roadshow	Global Forum	Global Regulatory Forum	Global Core Therapeutic Areas Ecosystem Forum	Radiopharmaceutical Innovation Forum	Global Supply Chain Innovation Forum	Innovative Process Technology Forum
	15:00-16:00		New Market Landscape	Innovative Technologies / Therapies	Korea Market Asia Market	Regulatory Affairs – APAC & Emerging Markets	Oncology	Clinical Development Future Manufacturing	Local Supply Chain Development	Cell Line Development & Construction
	16:00-17:00									
	17:00-18:00									
Mar13		Main Forum	BiOFUNDING Forum	Roadshow	Global Forum	Global Clinical Development Forum	Global Core Therapeutic Areas Ecosystem Forum	Immunology Innovation Forum	CMC Global Expansion Forum	Innovative Process Technology Forum
	09:00-10:00	MNC Strategy Release	Global BIO Investment	In Vivo CAR-T	Asia Market	Post-Deal BD Clinical Strategy	Neurological Disorders	Immunology Innovation	US & EU Markets	Purification Forum
	10:00-11:00									
	11:00-12:00		Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BiOFUNDING Forum	Roadshow	Global Forum	Global Clinical Development Forum	Global Core Therapeutic Areas Ecosystem Forum	Immunology Innovation Forum	CMC Global Expansion Forum	Innovative Process Technology Forum
	12:00-13:00	Strategic Release	Ecosystem & Innovation	Korea Session	Emerging Markets & Belt and Road Regions	Innovative Therapies: New Clinical Models	Metabolic Diseases	Autoimmune Diseases	CMC Global Expansion	Purification Forum Antibody CMC Development & Management
	13:00-14:00									
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BiOFUNDING Forum	Roadshow	Global Forum	Global Clinical Development Forum	Global Core Therapeutic Areas Ecosystem Forum	Immunology Innovation Forum	CMC Global Expansion Forum	Innovative Process Technology Forum
	15:00-16:00		M&A & IPO & Early-Stage Investment	Upstream Session	Russia Market	AI-Enabled Clinical Development	Ophthalmic Diseases	Treg & Nobel Prize Forum	CMC Global Expansion Forum Global Submissions & Regulatory Affairs	Upstream & Downstream Process Development
Mar14	16:00-17:00									
	17:00-18:00									
			Tax & Finance Law Forum	Roadshow	Global Forum	Innovative Formulation Development Forum	Scientific Achievement Translation Forum	Immunology Innovation Forum	Global Technology Transfer & Compliant Manufacturing Forum	Innovative Process Technology Forum
	09:00-10:00		Tax & Finance Strategies for Biopharma Companies	AI & Scientific Research	Middle East Markets LATAM Market	Antibody Drug Formulations & Inhalation Formulations: Regulatory and Process Considerations	Translational Practice of Biopharmaceutical Scientific Achievements	Frontier Research	Technology Transfer & Collaborative Manufacturing	ADC Process Development
	10:00-11:00									
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking		Networking	Networking
			Global IP Forum	Roadshow	Formulation Innovation Forum	Innovative Formulation Development Forum	Scientific Achievement Translation Forum		Global Technology Transfer & Compliant Manufacturing Forum	Innovative Process Technology Forum
	12:00-13:00		Global IP Strategy	Biomanufacturing		Novel Biologics: Formulation Manufacturing & Aseptic Processing	Sharing Practical Entrepreneurship Experiences by Professors		Submissions & Inspections	Analytical Testing Cleanroom &
	13:00-14:00								Commercial Manufacturing	Engineering Equipment

BIOCHINA 2026 (11th Edition) Agenda

	Time	Room F312	Room E309	Room E308	Room E311	Room E310	Room F313	Room F314	D3 Brainstorm 1	D3 Brainstorm 2	Main Stage 1	Main Stage 2
Mar12		Small Molecule Drug Innovation Forum		AI Innovation Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Exosome Innovative Development Forum	Biomanufacturing Innovative Development Forum	/	/		
	09:00-10:00	/ Opening Panel Discussion	Opening Panel Discussion	/ Opening Panel Discussion	/ Opening Panel Discussion	/ Opening Panel Discussion	/	/ Opening Panel Discussion	/	/	BIOCHINA Awards: Annual Supplier Ceremony	/
	10:00-11:00											
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA International Dialogue	BIOCHINA Bio Festival Runway Show
		Small Molecule Drug Innovation Forum	Oligonucleotide Drug Innovative Development Forum	AI Innovation Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Exosome Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
	12:00-13:00	Innovative Drug Development & Global Expansion	Case Sharing Indication	New Drug R&D	Complex Molecule Innovation & Development	Clinical Development	Technological Innovation & Clinical Translation	Food Development	Peptides	In Vivo CAR-T	/	/
	13:00-14:00											
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA Bio Festival	BIOCHINA International Supply & Procurement Dialogue
		Small Molecule Drug Innovation Forum	Oligonucleotide Drug Innovative Development Forum	AI Innovation Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Exosome Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
	15:00-16:00	Undruggable Targets Molecular Glues	Technology Development & CMC Strategies	New Drug R&D	Bispecific & Multispecific Antibody Innovation & Development	Innovative R&D	Delivery Clinical Translation Process Development	Food Development	Antibody CMC	Immune Cell, Cold Chain Logistics & Cell Therapy Quality Control	/	/
16:00-17:00												
17:00-18:00												
Mar13		Small Molecule Drug Innovation Forum	Peptide Drug Innovative Development Forum	XDC Drug Innovative Development Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Cell Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
	09:00-10:00	Oncology Drugs	Oral Cyclic Peptides Case Sharing	Global Development & Collaboration	Bispecific & Multispecific Antibody Innovation & Development	Drug Delivery	Future of Manufacturing	Agricultural Innovation	Drug Delivery	Radiopharmaceuticals	/	/
	10:00-11:00											
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA CEO Dialogue	BIOCHINA Bio Festival Awards
		Small Molecule Drug Innovation Forum	Peptide Drug Innovative Development Forum	XDC Drug Innovative Development Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Cell Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
	12:00-13:00	Multi-Indication	Case Sharing	Latest R&D & Clinical Progress	Bispecific & Multispecific Antibody Innovation & Development	Process & Clinical Research	Autoimmune & Other Disease Drug Development	Pharmaceutical Synthesis	Conjugated Drugs	Artificial Intelligence	/	/
	13:00-14:00											
	14:00-15:00											
		Small Molecule Drug Innovation Forum	Peptide Drug Innovative Development Forum	XDC Drug Innovative Development Forum	Antibody Drug Innovative Development Forum	Stem Cell Drug Innovative Development Forum	Cell Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
	15:00-16:00	Clinical Indication Development –CNS CMC & Quality	Process & Manufacturing	Differentiated Targets & Molecular Design Cutting-Edge Technology Development & Application ADC Pathology Research	Antibody Combination Therapy: From Early Research to CMC Management	Industry Policy & Translation	Solid Tumor Drug Development	Bioaesthetics	Conjugated Drugs	Organoids	/	/
16:00-17:00												
17:00-18:00												
Mar14		AI for Science Forum	Nucleic Acid Drug Innovative Development Forum	XDC Drug Innovative Development Forum	Regenerative Medicine & Tissue Repair Forum	Stem Cell Drug Innovative Development Forum	Gene Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
	09:00-10:00	Basic Research and Core Technology Integration	mRNA Cancer Vaccines	Novel Molecule Design & Development	Regenerative Medicine Empowering Tissue Repair	iPSC	Technological & Clinical Innovation	AI & Biomanufacturing	Cell Therapy CMC & Regulatory	Antibody R&D & Autoimmune Diseases	/	/
	10:00-11:00											
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA CMO Dialogue	BIOCHINA CTO Dialogue
		AI for Science Forum	Nucleic Acid Drug Innovative Development Forum	XDC Drug Innovative Development Forum	Regenerative Medicine & Tissue Repair Forum	Stem Cell Drug Innovative Development Forum	Gene Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2
12:00-13:00	Drug Discovery and Clinical Translation Session	mRNA Potential Development Technology Innovation Delivery & Future Applications	Innovative Development & New Technologies	Organoids & Tissue EngineeringRegenerative Medicine Empowering Tissue Repair	MSC	Indication Development CMC & Regulatory Submission	AI & Biomanufacturing Accelerating Life Science Research	Cell Therapy Quality Stem Cells	Small Molecule Innovation & Development			
13:00-14:00												

BIOCHINA2026 Main Forum

Date	March 12th	March 13th
09:00-14:00	09:00-09:20 BIOCHINA Opening Ceremony Guest of Honor: Deepa Talpade, Bayer Pharmaceuticals, SVP and Head BD&L and Alliance Management, Oncology and Radiology Dr. Lianshan Zhang, Jiangsu Hengrui Pharmaceuticals, Board Member & Vice President 09:20-09:40 BIOCHINA Opening Speech Speakers: Frank Jiang, M.D., Ph.D., Jiangsu Hengrui Pharmaceuticals, EVP, Chief Strategy Officer, Board Director Huji Xu, Changzheng Hospital, Professor Friedemann Janus, Ph.D., Bayer Pharmaceuticals, SVP and Global Head of Bayer Co.Lab, Regional BD&L and Divestitures	09:00-11:00 MNC Strategy Release Speaker: Albert Ren, Pfizer, Vice President Worldwide Business Development China
	9:40-10:40 Panel Discussion: Power of Innovation – A Global Perspective on Disruptive Technologies Moderator: Dr. YongJun Liu, Xiaolu Biomedicine Co., Ltd, Founder Panelists: Michel GILLIET, CHUV Lausanne University Hospital, Chairman Jenny Ting, The University of North Carolina at Chapel Hill, Professor, Co-Founder of IMMvention Therapeutix 10:40-11:10 Presentation: New Strategies and Emerging Trends in Immunotherapy Speaker: Zhigang Tian, Chinese Academy of Engineering, Academician 11:10-11:30 BIOCHINA Awards Ceremony	11:00-12:00 Panel Discussion: Building a Global Partnership Ecosystem Together Moderator: Weimin Liu, BeOne Medicines Ltd., MD, Life Science VC Panelists: Ryan Wang, Eli Lilly, Vice President, Lilly China Innovation and Partnerships. Faisal Darwazeh, Hikma Pharmaceuticals, Vice President Group Business Development & Alliances Zhongyuan Zhu, Duality Biotherapeutics, Inc., Founder, Chairman & CEO Betty Huang, Bayer Pharmaceuticals, VP and Head of Collaborate to Cure Hub China
	11:30-12:30 Panel Discussion: How Can Chinese Pharmaceutical Companies Embrace Globalization? Moderator: Jiang Zhang, LongRiver Investments, Founder & CEO Panelists: Aimin Hui, PhD, EnCureGen Pharma, Chair and CEO Yan Liu, Takeda Pharmaceuticals, President, China Zhisheng Chen, WuXi Biologics (Cayman) Inc., CEO & Chairman, WuXi / WuXi Healthcare Alliance 12:30-13:00 Panel Discussion: How is AI Transforming the Biopharmaceutical Industry? Panelists: Feng Ren, InSilico Intelligence, Co-CEO Runping Guo, Microsoft China, General Manager, Azure Intelligent Cloud Solutions	12:00-13:00 MNC Strategy Release Speakers: Faisal Darwazeh, Hikma Pharmaceuticals, Vice President Group Business Development & Alliances Atul Raut, Sun Pharma, Vice President Dr.Satheeshkumar Sriharan, Dr.Reddy's Laboratories, Group Country Head 13:00-14:00 Strategy Release Cytiva Sitofan Strategic Release: Driving Bioprocess Innovation Speaker: Cytiva
Concurrent Events	March 12, 18:00-20:00 BIONIGHT 2026 (Exclusive Invitation Dinner) March 12-14 BiOPARTNERING 1V1 Targeted Meetings March 12-14 BIOCHINA 2026 Exhibition	

BIOCHINA2026 BioBD Forum		BIOCHINA2026 BioFUNDING Forum	BIOCHINA 2026 Tax & Finance Law Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	BIOFUNDING Forum 09:00–09:20 Presentation: Global Trends in Biopharma Investment and Financing 09:20-10:10 TOP Fund Discussion: BIO Investment Keywords for 2026 Panelists: Marc Appel, Pacific Bridge NY, Managing Partner Jerry Wu, LongRiver Investments, Managing Director 10:10-11:00 Dual-Currency Healthcare Funds: How to Invest Overseas? Moderator: Xiaohang Tong, Decheng Capital, Partner Panelists: Jieyu Zou, Lilly Asia Ventures, Managing Director Henry He, HighLight Capital, CIO, Partner Lixin Xu, Mingxin Capital, Managing Partner Dr. Dan LIU, Pivotal BioVenture Partners, Managing Partner	Fiscal and Tax Strategies for Chinese Innovative Drug Companies from a BD Perspective 09:00–09:20 Presentation: Tax Planning in Overseas BD Transactions and M&A Exits of Chinese Pharmaceutical Companies Speaker: Chen Wang, Deloitte, Head of International Tax & M&A Tax, East China, Senior Partner 09:20–09:40 Presentation: The Story Behind the Valuation of Chinese Innovative Drug Companies Speaker: Xuan Wang, Deloitte China, Partner, M&A Financial Advisory 09:40–10:00 Presentation: Legal Hot Topics in BD Transactions of Chinese Pharmaceutical Companies Speaker: Hao Zhao, JUN HE LAW OFFICES, Partner 10:00–11:00 Panel Discussion: International Tax Planning for Biopharma IP License-Out and NewCo Transactions Moderator: Yimin Zhao, Deloitte China, Tax Lead Partner, Life Sciences Panelists: Shu Zhang, Deloitte China, International Tax Partner, Life Sciences Jingna Chen, Deloitte China, China Tax Partner, Life Sciences Yiming Liu, Cooley, Managing Partner, Shanghai
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	BD Strategy 12:00–12:30 Presentation: Insights into BD Deals for Innovative Drugs in China and Global Enablement Speaker: Jean-Baptiste Duval, the CFI Group, Director Healthcare & Life Sciences 12:30–13:15 MNC Asia-Pacific Strategy Moderator: Jean-Baptiste Duval, the CFI Group, Director Healthcare & Life Sciences Panelist: Feng Bian, BMS, Executive Director Jenny Yang, Novo Nordisk A/S, Head of External Innovation Asia Pacific 13:15–14:00 Global Strategies Of Chinese Big Pharma & Biotech Moderator: Mingde.xia, Innolake Biopharm, CEO Panelists: Vivian Feng, Fosun Pharma, General Manager of BD Mingjiu Chen, PhD, Biosion Inc., Founder, President & CEO Tony Xue, MediLink Therapeutics, Co-Founder and CEO	12:00–13:00 LP–GP–Biotech Ecosystem: Aligning Policy, Capital, and Innovation Moderator: Yang Yu, Deloitt China, CGO, Audit & Assurance Panelists: Xi Yang, Guangzhou Guoju Venture Capital Co., Ltd., Chairman of the Board Chong Zhang, Green Pine Capital., Partner of the Healthcare Fund Pai Zhu, EFUNG CAPITAL, CEO Fei Qi, Ph.D., LEGEND CAPITAL, Executive Director 13:00–14:00 Big Pharma Innovation Radar: Scanning, Investing in, and Incubating the Future Moderator: Han Dai, Viva BioInnovator, CIO & Head of Investment Panelists: Di Xu, Bayer Co.Lab, China Head Congyang Wu, AbbVie Ventures, Head of Strategy & Operations Liheng Ma, Pfizer, Head of DC Strategy & CGRP Therapeutics Zhaoying Xu, Ph.D., Lilly Ventures, China, Executive Director Dr. Jonathan Liu, BeOne Innovation Center / BeOne Biologics / BeOne China BioVentures, CEO / Chairman & GM / Managing Director	Global IP Strategies of Chinese Innovative Drug Companies from a BD Perspective 12:00–12:20 Presentation: Value Realization: IP Due Diligence, Valuation, and Risk Allocation in Global BD Transactions Speaker: Wengian Wu, Deloitte, Financial Advisory Partner 12:20–12:40 Presentation: Strategy First: A BD-Driven Blueprint for Global IP Deployment Speaker: Yang Gu, HAN KUN LAW OFFICES, Partner 12:40–13:00 Presentation: Offense and Defense: Building a Practical IP Framework to Support BD Transactions and Market Access Speaker: Adrian Murray, Brand Murray Fuller LLP, Partner 13:00–14:00 Panel Discussion: Bridging the Gap: Seamless Alignment of IP, BD, and Commercialization Moderator: Yang Gu, HAN KUN LAW OFFICES, Partner
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	15:00-15:15 Presentation: Topic TBC Speaker: Tony Cheng, Ph.D, Custom solutions, Norstella China 15:15-16:15 The Evolution and Beyond of NewCo: Multi-Dimensional Collaboration Between MNCs and Chinese Innovative Pharma Companies Moderator: Jielun Zhu, Excalipoint Therapeutics, Co-Founder, CFO & CBO Panelists: Dato Liu, Maiwei Biotech, Chairman & General Manager Chenbing Wu, EpimAb Biotherapeutics Inc, CEO Friedemann Janus, Ph.D., Bayer Pharmaceuticals, SVP and Global Head of Bayer Co.Lab, Regional BD&L and Divestitures Market New Landscape 16:15-17:00 Breaking Boundaries in China: Pathways and Practices for Globalizing Innovative Products (In China, for Global) Moderator: Dr.Satheeshkumar Sriharan, Dr. Reddy's Laboratories, Group Country Head Panelist: Hua Jiang, Boan Biotech, Chairlady and CEO Dr. Lianshan Zhang, Jiangsu Hengrui Pharmaceuticals, Board Member & Vice President Hao Jiang, CSPC Pharmaceutical, General Manager, Business Development Wei Huang, Henlius Biotech, President 17:00-18:00 Breaking Through Innovative Drug Reimbursement Planner: Jiang Zhang, LongRiver Investments, Founder & CEO Panelists: Feiqing Chu, AIA, Head of Health Management Division Chao Guo, Pacific Life Insurance, Deputy General Manager Lin Zhang, Pulan Technology, Founder & CEO	15:00–16:00 New Landscape of Industrial Investment: Alliances and Strategic M&A Moderator: Yueyue Wang, Tianchao Capital, Partner Panelists: Peng Lin, China Resources Biopharmaceutical Company, Deputy General Manager Tse Hsin, Sino Biopharmaceutical Limited, Executive Director Zhisheng Chen, CEO of WuXi Biologics & Chairman of WuXi Head & WuXi AppTec Holdings 16:00-17:00 Panel Discussion: Investor Dialogue – TGIF Moderator: Jia Li, Lang Sheng Investment Group, Partner Panelists: Jielun Zhu, Excalipoint Therapeutics, Co-Founder, CFO & CBO Xinle Niu, Huajin Capital, CIO, Healthcare Jayson Lee, LongRiver Investments, Partner 17:00–17:30 Presentation: Key Financial Issues in Hong Kong IPOs of Biopharma Companies Speaker: Lanying Mu, Deloitte, Managing Partner, Audit, China Life Sciences 17:30–18:00 Presentation: US Tax Planning for Founder and Management Equity Incentive Programs Before and After Biopharma IPOs Speaker: Xuejia Shao, Deloitte, Partner, U.S. Tax, Private Equity & Life Sciences	
			<div>Back to Contents</div> <div>13</div>

BIOCHINA2026 Global Forum			
Date	March 12th	March 13th	March 14th
09:00-11:00	<p>09:00-10:00 Exhibition Hall Closed During Opening Ceremony</p> <p>Australia Market 10:00-10:15 Keynote Presentation – Australian Biotech Overview: Trend, Popular Exits, and New Model Speaker: Betty Zhang, Boson Ventures, Investment Manager (Healthcare) 10:15-11:00 Panel Discussion: How Biotech start ups can navigate cross-border collaboration between China and Australia Moderator: Betty Zhang, Boson Ventures, Investment Manager (Healthcare) Panelists: Professor Jian Li, Biomedicine Discovery Institute, Monash University, Professor & Head of the Antimicrobial Systems Pharmacology Laboratory Dr. Anne Laure Puaux, Walter and Eliza Hall Institute (WEHI), CEO, WEHI Ventures & Head of BD, WEHI Dr Marthe D'Ombain, CSL, Executive Director and Head of Global Research Innovation Stuart Dignam, MTPConnect, CEO Dr. Anushi Rajapaska, Misti, Founder & CEO</p>	<p>Asia Market 09:00–09:10 Opening Presentation Speaker: Yunke Song, Syneos Health, Managing Director of Consulting 09:10–09:50 Pharma Strategic Alliance Panel Moderator: Douglas Campbell, Mochida Pharmaceutical, Principal Scientist & Senior Staff, R&D Alliances Panelists: Seunghwan Song, Chugai Pharmaceutical, Senior Manager, Global Business Analyst Sean William Ryan, MD, Tanabe Pharma America, Inc., Chief Business Officer 09:50–10:50 CGT Panel Panelists: Hiroshi Yamaguchi, Greenstaff Life Science (ICG Medical), Global Head of Life Science Kobayashi Miho, ADL, Manager Blumenthal Yukari, Astellas, Gene Therapy Director Yoshiyuki Saito, N-of-One Pharmaceuticals Inc., CEO & Founder</p>	<p>Middle East Market 9:00-9:20 Keynote Presentation – Middle East Ecosystem Landscape Speaker: Haytham alRashed, Unifusion Business Service Co, Managing Director and Regulatory Affairs Head 9:20-10:00 Panel Discussion: Regional Regulations, market entry strategies, and pharma business development in Middle East Moderator: Lulu Manasseer, Alnylam Pharmaceuticals,Inc, Business Consultant and Principal Associate Scientist Panelists: Joe Henein, NewBridge Pharmaceuticals, President and CEO Hosam Dib, Bioscience Pharma, CEO Kareem S. Darwazah, Hikma Pharmaceuticals, VP, BD & Alliance Management – MENA Mohammed Jobran, PharmaKnowl Consulting, Regulatory Affairs Consultant, CEO & Principal Consultant</p> <p>LATAM Market 10:00-11:00 Panel Discussion: Focus Business Development, Licensing, and Collaboration Opportunities with Latin American Pharma Companies Panelists: Joao Siffert, Eurofarm, Head of R&D, CEO, Director Juan, Vigenius, Founder Dr.Dhaval Soneji, Gan & Lee Pharmaceuticals, Director Paulo Fernandes, AZD CRO A2Z Clinical Research Site, Chief Operating Officer Lisa Palla Tavoraro, FAXE Group – Logistics for Clinical Trials, Global Director, Business Development</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p>Korea Market Opening Session- China and Korea Collaboration & Investment – Opportunities and Highlights 12:00-12:20 Keynote Presentation - Highlight Capital (Korea & China) Speaker: Lee, Highlight Capital, Principal 12:20-13:00 Panel Discussion – China–Korea Collaboration Opportunities Moderator: Lee, Highlight Capital, Principal Panelists: Soyong Jang, Celltrion Inc, R&D Business Development Director Hun Kim, SK Bioscience, President Dr. Sungwan Hwang, SK Biopharmaceutical, CTO 13:00 – 13:20 Keynote Presentation –ITP 13:20 – 13:40 Keynote Presentation Speaker: KHIDI China 13:40 – 14:00 Keynote Presentation</p>	<p>Emerging Markets & Belt and Road Regions 12:00–12:20 Opening Keynote-Innovation Licensing & Cross-Border Collaboration Opportunities Speaker: Mayur Sangwai, Dr. Reddy's Laboratories, Head of BD – Innovation Licensing 12:20–13:10 Panel Discussion-Belt and Road Regions: BD, Licensing & Manufacturing Opportunities in the China Market Panelists: Mayur Sangwai, Dr. Reddy's Laboratories, Head of BD – Innovation Licensing Lama A. Shatar, Hikma Pharmaceuticals, Sr. Director, BD & Alliance Management – MENA Songpon Deechongkit, Ph.D., Siam Bioscience Company Limited, CEO 13:10-14:00 Panel Discussion- Regulatory Landscape & Market Access in Emerging Belt and Road Regions Moderator: Julia Sardaryan, Smooth Drug Development, CEO Panelists: Dr. Obaidullah, PhD, MPH, Drug Regulatory Authority of Pakistan (DRAP),CEO Dr. Akhtar Abbas Khan, PhD, Drug Regulatory Authority of Pakistan (DRAP), Director and Head Pharmacy Services (Clinical Trials) and Pharmacovigilance Center Kamran Khan, Smooth Drug Development, BD Director</p>	
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p>Korea Market BD & Licensing Collaboration and Innovation Models 15:00 – 16:00 Panel Discussion – Biotech Collaboration: BD and Co-development Models Moderator: Marc Appel, Pacific Bridge, Managing Partner Panelists: Nam-Gu Her, AIMED BIO, CEO Nari Yun, GI Innovation, Vice president Paul Song, Genequantum Healthcare, CSO Tingke tang, Joincare pharamaceutical, Vice President</p> <p>Asia market 16:00-16:20 Keynote Presentation 16:20-17:20 Panel Discussion – BD Collaboration between China and Other Asian Regions Moderator: Ling Tong, Buchang BioPharma, BD VP/ Head Panelists: Mayur Sangwai, Dr. Reddy's Laboratories, Head BD - Innovation Licensing Manoj Thombare, Sun Pharma Laboratories Ltd, Senior General Manager and Business Development & Licensing Aniruddh Galgali, Cipla Limited, Head of Strategy, Projects, Licensing & M&A 17:20-18:00 Panel Discussion – Supply Chain Collaboration between China and Other Asian Regions Panelist: Dr. SAMBASHIVA D, Abhignya Biotech Pvt Ltd, Founder</p>	<p>Russia Market 15:00-15:20 Opening Remarks 15:20-16:20 Panel Discussion- BD & Licensing Announcements Moderator: Alexander Nozdrachev, Innovant Bio, Managing Partner Panelists: Svetlana Gogoleva, JSC “Akrikhin”, Head of BD & Licensing Svetlana Bolsheva, Binnopharm Group, LLC, Strategy & Business Development Director Alexandr Gorynin, Nizhpharm JSC, Head of M&A BD&L department Vadim Ryabokon, R-Pharm, Vice President of Strategic Project Development Sergey Morozov, PIQ-Pharma Group, Business Development Head Igor Volkov, Nanolek, Head of Business Development Igor Borisenko, R-Pharm, Retail Business Head 16:20-17:20 Innovation and Supply Chain collaboration Panelist: Vladimir Popov, ROSBIOTECH & ESMAR Ltd., Professor & CEO 17:20- 17:40 Q&A</p>	
Concurrent	March 12th–14th BIOCHINA2026Exhibition	March 12th–14th BiOPartnering 1V1Meeings	Back to Contents 14

BIOCHINA2026 Global Regulatory Forum		BIOCHINA2026 Global Clinical Development Forum	BIOCHINA2026 Innovative Formulation Development Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Post-BD Clinical Strategy Planner: Yongjiang Hei, CSPC Pharmaceutical Group, CMO 09:00-09:20 Presentation: Clinical Strategy After BD Transactions 09:20-09:40 Presentation: Global Clinical Regulatory Submission Strategies Speaker: Yongjiang Hei, CSPC Pharmaceutical Group, CMO 09:40-10:00 Presentation: Key Considerations for MRCT Clinical Trials 10:00-11:00 Panel Discussion: Global Clinical Development Strategies for China's Innovative Drugs Panelists: Yongjiang Hei, CSPC Pharmaceutical Group, CMO Goh Ak Han, Simcere Pharmaceutical Group Limited, CMO Wei Zhu, BioRay Pharmaceutical Co., Ltd., CMO Ming Shi, Shanghai Hutchison Pharmaceuticals, CMO Steve Chin, MediLink Therapeutics, CMO Jin Li, Shanghai Henlius Biotech, Inc., Vice President, Regulatory Affairs	Antibody Drug Formulation Development, Inhalation Formulation Regulation and Process Innovation 09:00-09:20 Presentation: From ADC to XDC — Challenges in Conjugated Drug Product Development Speaker: Chunyuan Jia, WuXi XDC, Head of Bioconjugate Product Development Team 09:20-09:40 Presentation: High- and Ultra-High Concentration Antibody Formulation Development 09:40-10:00 Presentation: Current Status of Inhalation Formulation Regulation Speaker: Guiliang Chen, Shanghai Center for Drug Evaluation and Inspection, Chief Pharmacist 10:00-10:20 Presentation: Challenges in Developing Improved Inhalation Formulations and Industrialization Barriers Speaker: ZhenBo Tong, Southeast University, Professor 10:20-10:40 Presentation: Dual-Chamber Lyophilized Formulation Technology Speaker: Yan Jiang, VISEN Pharmaceuticals, Head of Formulation 10:40-11:00 Q&A Session
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	12:00-14:00 WuXi AppTec Special Session	Innovative Therapy: New Clinical Models Planner: Yongjiang Hei, CSPC Pharmaceutical Group, CMO 12:00-12:20 Presentation: Upgrading Clinical Study Design under the New IIT Regulations 12:20-12:40 Presentation: Global Expansion – International Multi-Center Clinical Collaboration Strategies for Innovative Therapies 12:40-13:00 Presentation: New Globally Successful Clinical Models: Integrated Practices in Canada Speaker: Jennifer Lai, Consul and Trade Commissioner, Consulate General of Canada in Shanghai 13:00-14:00 Panel Discussion: Innovative Models and Challenges under the New IIT Regulations Panelists: Huji Xu, Changzheng Hospital, Professor Anbo Xiang, CSPC Pharmaceutical Group, President of Clinical Division & Non-Oncology CMO Limin Wen, Simnova, SVP Zonghai Li, CARsgen, Founder&CEO Jie Chen, IASO BIO, CMO Jinghua Zhao, Fosun Kairos, CMO	Novel Biologics 12:00-12:20 Presentation: Research Progress and Technical Challenges of Long-Acting Peptide Formulations Speaker: Xiaojun Zhang, CSPC Pharma, Director, 4th Pharmaceutics Institute, Beijing R&D Center 12:20-12:40 Presentation: Strategies for Long-Acting Peptide Formulations Speaker: Mingqiang Rong, Chengdu Peide Biopharmaceutical Co., Ltd., Chairman 12:40-13:00 Presentation: Application of Innovative Drug Solid Dispersion Formulation Development in Preclinical and Clinical Studies Speaker: Kunlin Wang, Allorion Therapeutics, Senior Scientist, CMC Formulation Production & Aseptic Processing 13:00-13:20 Presentation: Interpretation of the Latest Aseptic Appendix Policies Speaker: Hongyu Tan, Senior Pharmaceutical GMP Expert, Former Core Inspector at CFDI 13:20-13:40 Presentation: Structure and Development of Enterprise CCS Documentation Speaker: Weifeng Lu, Junshi Lingang site, Quality Head and Authorized Quality Representative 13:40-14:00 Presentation: Case Sharing on Facility Construction and Aseptic Inspection Readiness 14:00-15:00 Panel Discussion: Aseptic Process Validation, APS, and Aseptic Interventions Panelists: Hongyu Tan, Senior Pharmaceutical GMP Expert, Former Core Inspector at CFDI Ji Yu, TJ Biopharma, VP of Manufacturing
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	APAC & Emerging Market Regulations 15:00-16:00 Pakistan: Pharmaceutical Manufacturing and Regulatory Affairs 16:00-16:30 Presentation: Regulatory Oversight of Pharmaceutical and Biological Manufacturing in Indonesia Speaker: Shanti Marlina Sibuea, Ph.D., Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control - BPOM 16:30-17:00 Panel Discussion: Topic TBC Moderator: Ding Liu, Qilu BioPharma, Deputy General Manager Panelist: Shanti Marlina Sibuea, Ph.D., Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control - BPOM 17:00-18:00 Saudi Arabia	AI-Driven Clinical Development Planner: Yongjiang Hei, CSPC Pharmaceutical Group, CMO 15:00-15:20 Presentation: AI-Enabled Digital Clinical Testing for Drugs: Exploring New Paths and Practices in Precision Medicine Speaker: Zhong Pei, The First Affiliated Hospital of Sun Yat-sen University, Deputy Director, Department of Neurology 15:20-15:40 Presentation: Intelligent Electronic Medical Records – Clinical Data Value Extraction and Compliance Practices 15:40-16:00 Presentation: Virtual Clinical Trials Guided by Computational Medicine Speaker: Yu Zhao, Phil Rivers Tech, Co-Founder & Deputy Director, Turing-Darwin Lab 16:00-17:00 Panel Discussion: Cross-Industry Dialogue – Collaborative Innovation and Challenges in AI Clinical Trials Panelists: Yu Zhao, Phil Rivers Tech, Co-Founder & Deputy Director, Turing-Darwin Lab Dr. Li Wang, Xuanzhu Biopharmaceutical Co., Ltd., CMO, deputy general manager Xiaojing Sun, Pfizer, Head of Clinical Trial Solutions & Strategy Team 17:00-18:00 Panel Discussion: Data-Driven Approaches – Integrating Electronic Medical Records with Real-World Evidence	

BIOCHINA2026 Global Core Therapeutic Areas Ecosystem Forum			BIOCHINA 2026 Scientific Achievement Translation Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Neurological Disorders Planner: Xianbo Zhou, AstraNeura, Co., LTD., Founder&CEO 09:00–09:20 Presentation: Targeting TRPM7 Channel-Enzyme to Treat Neurodegenerative Disorders Speaker: Nashat Abumaria, Fudan University Shanghai Medical College, Independent Researcher, Institute of Brain Science 09:20–09:40 Presentation: Research on Biomarkers in Alzheimer's Disease Speaker: Jiong Shi, Vice President, First Affiliated Hospital of University of Science and Technology of China 09:40–10:00 Presentation: Neuroinflammation and Central Nervous System Disorders: Mechanistic Exploration and Novel Intervention Strategies 10:00–11:00 Panel Discussion: Breaking Through CNS Innovative Drug R&D – From Targets to Commercialization: Synergies and Challenges Moderator: Xianbo Zhou, AstraNeura, Co., LTD., Founder & CEO Panelists: Gary Tong, Takeda R&D China and APAC Region, VP, Clinical Development Head Chenyang Wu, Pivotal BioVenture Partners, Investment Director POE-JOU CHEN, Cali Biosciences, Co-Founder and CEO Zhaomin Chen, SIBR, External Innovation Lead Jiong Shi, The First Affiliated Hospital of University of Science and Technology of China, Vice president	09:00–11:00 Translational Practice of Biopharmaceutical Scientific Achievements 09:00–09:20 Presentation: Overcoming the Challenges of Translating High-End Biopharma Achievements: IP Strategy and Value Realization Mechanisms at Guangzhou Laboratory Speaker: Ping Liang, Guangzhou Laboratory, Director, Technology Transfer Department 09:20–09:40 Presentation: The “Pharma University Plan” for Translating New Drug R&D Achievements — Lessons from Typical Case Studies Speaker: Weijun Zhao, Ph.D., Chinese Society of Toxicology, Assistant Researcher, Master's supervisor, Certified Toxicologist 09:40–10:00 Presentation: Translating Scientific Achievements in Research Hospitals and Building Proof-of-Concept Service Systems Speaker: Juan Lei, West China Medical Center, Sichuan Medical University, Director 10:00–11:00 Panel Discussion: Bridging the “Last Mile” of Research Translation — Collaborative Innovation between National Platforms and Universities/Hospitals Panelists: Ping Liang, Guangzhou Laboratory, Director, Technology Transfer Department Weijun Zhao, Ph.D., Chinese Society of Toxicology, Assistant Researcher, Master's supervisor, Certified Toxicologist Juan Lei, West China Medical Center, Sichuan Medical University, Director Dr. Weijun Shen, Changping National Laboratory, Director of the Center for Translational Research
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Oncology 12:00–12:20 Presentation: Development of Universal Cancer Vaccines Speaker: Yong Yang, China Pharmaceutical University, VP 12:20–12:40 Presentation: TBC 12:40–13:00 Presentation: Tumor Drug Resistance Mechanisms and Exploration of Combination Therapy Strategies 13:00–14:00 Panel Discussion: Deepening Targets — Maximizing Clinical and Commercial Value Panelists: Dr. Guoxiang Wu, Novatim, Founder, Chairman and CEO Zig LANG, Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd, Vice President	Metabolic Disease Drugs Research Session 12:00–12:20 Presentation: GLP-1 Multi-Target “Arms Race” – In-Depth Analysis of MNC Strategies and How Domestic Novel Drugs Can Break Through Competition Speaker: Weiwei Mi, DXY Insight Database, Head of Innovative Drug Data Dept. 12:20–12:40 Presentation: TBC Speaker: Linong Ji, Professor of Medicine at Peking University, Director of Peking University Diabetes Center 12:40–13:00 Presentation: TBC 13:00–14:00 Clinical Session Panelists: Linong Ji, Professor of Medicine at Peking University, Director of Peking University Diabetes Center	Sharing Practical Entrepreneurship Experiences by Professors Planner: Dr. Weijun Shen, Changping National Laboratory, Director of the Center for Translational Research 12:00–12:20 Presentation: Molecular Glue Drugs: From Basic Research to Clinical Translation Speaker: Yong Cang, Degron Therapeutics, Co-Founder & CSO, Professor of ShanghaiTech University 12:20–12:40 Presentation: The Entrepreneurial Journey of Shenxi Biotech Speaker: Gong Chen, NeuExcell Therapeutics, Founder & Chairman 12:40–13:00 Case Sharing 13:00–14:00 Translational Strategies and Practical Entrepreneurship of Professors Panelist: Qingsong Zhu, 五针松医药, Co-Founder & CEO
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Bayer Session 15:00-18:00 Cardiovascular & Renal Diseases (Tentative)	Ophthalmic Diseases 15:00–15:20 Presentation: Clinical Needs in Retinal Diseases 15:20–15:40 Presentation: Clinical Needs in Ocular Surface Diseases 15:40–16:00 Presentation: Clinical Progress and Challenges of Gene Therapy Applications in Ophthalmic Diseases Speaker: Fenghua Wang, Innostellar Biotherapeutics Co.,Ltd, CEO 16:00–16:20 Presentation: TBC Speaker: Haidi Hu, Arctic Vision, Founder, Chairman & CEO 16:20–16:40 Presentation: TBC Speaker: Jiongguang Chen, Oculgen Biomed Ltd., Founder & CEO 16:40–17:40 Panel Discussion: Innovative Development in Ophthalmic Diseases Panelists: Dr. Jack Wu, Ocusun Biotechnology, CSO Dr. Hongwei Peng, Jingze Biopharma Chairman & Founder Haidi Hu, Arctic Vision, Founder, Chairman & CEO Jiongguang Chen, Oculgen Biomed Ltd., Founder & CEO	

BIOCHINA 2026 Radiopharmaceutical Innovation Forum		BIOCHINA 2026 Immunotherapy Innovation Forum	
Date	March 12th	March 13th	March 14th
09:00-11:00	Future Exploration – Radiopharmaceutical Development from a BD Perspective Planner: Novartis 10:00–11:00 Panel Discussion: Next Waves in RLT Research and Business Development Moderator: David Chen, BFC GROUP, Managing Director & Co-Founder Panelists: Shona Whyte, Novartis Marcel Reichen, Ratio Therapeutics Tao Yu, LAV, Principal Zhibo Liu, Peking University, Professor, School of Chemistry and Molecular Engineering Yunxia Yang, HongShan Capital Group, Partner	09:00–11:00 Immunotherapy Innovation Planner: Bing Su, Director, Shanghai Institute of Immunology 09:00–09:30 Presentation: Topic TBC Speaker: Youqiong Ye, Shanghai Jiao Tong University School of Medicine, Principal Investigator 09:30–10:00 Presentation: Topic TBC Speaker: Qiang Gao, Fudan University 10:00–10:30 Presentation: Mechanisms of Targeting Immune Checkpoints to Enhance Cancer Immunotherapeutic Efficacy Speaker: Yan Zhang, Shanghai Jiao Tong University School of Medicine/Shanghai Institute of Immunology, Principal Investigator 10:30–11:00 Presentation: Topic TBC	Frontiers in Future Biopharma Forum Planner: Chen Dong, Chinese Academy of Sciences, Academician 09:00-09:30 Presentation: Constructing Spatiotemporal Proteomes and Virtual Cells to Support Drug Discovery Speaker: Tiannan Guo, Westlake University School of Medicine, Tenure-track Associate Professor / Researcher 09:30-10:00 Presentation: TBC Speaker: Ju-Sheng Zheng, Westlake University School of Medicine, Tenured Associate Professor / Researcher; Executive Vice Dean, School of Future Biomedicine 10:00-10:30 Presentation: TBC Speaker: Chen Dong, Chinese Academy of Sciences, Academician 10:30–11:00 Presentation: The all-encompassing roles of innate immune receptor in health and diseases Speaker: Jenny Ting, The University of North Carolina at Chapel Hill, Professor, Co-Founder of IMMvention Therapeutix
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Innovative R&D – Ligand Selection and Early-Stage Development Planner: Novartis 12:00–12:20 Presentation: Innovative Industrial Development of Radiopharmaceuticals – From Molecule to Clinic Speaker: Ge Bai, Sinotau Pharmaceutical Group, Vice President 12:20–12:40 Presentation: Discovery of Bioactive Peptides and Their Applications in RDC Drugs Speaker: Yilong Li, PepLib, Vice President 12:40–13:00 Presentation: VanKeur Targeted Radiopharmaceutical R&D Platform (InnoRDC) and Project Updates Speaker: Dr. Ning Xi, FindCure, CEO 13:00–13:20 Presentation: From Innovation to Clinic – Entering the Era of Integrated Precision Therapy: Development of Radioligand Conjugates Speaker: Bo Shan, BoomRay, CEO 13:20–13:40 Presentation: Discovery of c-Met Targeted ¹¹¹ In/ ²²⁵ Ac Theranostic Radiopharmaceuticals Speaker: Dr. Fa Liu, Full-Life Technologies, CSO 13:40–14:00 Presentation: Seamless Integration of Global FIC and China FIH to Empower Global RLT Innovation Collaboration Speaker: Ivy Chao, C Ray Therapeutics	12:00–14:00 Autoimmune Diseases 12:00–12:30 Presentation: Dermatology Research Speaker: Michel Gilliet, CHUV Lausanne University Hospital, Chairman, 12:30–13:00 Presentation: From Red Ocean to Blue Ocean: Decoding High-Potential Targets for Autoimmune Therapy in China Speaker: Zhong Zhao, DXY Insight Database, BU Head & Chief Product Officer 13:00–14:00 Endocrine Diseases	
14:00-15:00	Networking & Events	Networking & Events (March 13 th)	
15:00-18:00	Clinical Development – Precision Matching of Radionuclide Selection and Clinical Indications 15:00–15:20 Presentation: Radionuclide Therapy for Thyroid Cancer and Other Diseases Speaker: Hongcheng Shi, Director, Department of Nuclear Medicine, Zhongshan Hospital, Fudan University 15:20–15:40 Presentation: Frontiers and Clinical Translation of PSMA-Targeted Theranostics Speaker: Shaoli Song, Fudan University Shanghai Cancer Center, Director of the Department of Nuclear Medicine 15:40–16:40 Panel Discussion: Practical Considerations in Radionuclide Selection and Clinical Matching Panelists: Dianjun Chen, Ph.D., StarRay Therapeutics, President & CSO Hongcheng Shi, Zhongshan Hospital, Fudan University, Director, Department of Nuclear Medicine Shaoli Song, Fudan University Shanghai Cancer Center, Director of the Department of Nuclear Medicine Future Manufacturing – Radiopharmaceutical CMC & Industrialization 16:40–17:40 Future Commercialization Strategies for Radiopharmaceuticals Panelists: Tao Xu, Ph.D., Suzhou SmartNuclide, Founder & CEO Bo Shan, BoomRay, CEO Min Hong, JunKangLiTai Biosciences, General Manager Susan Wang, Nuruit Medical Technology Co., Ltd., CBO Zheng Wang, Theranosta Inc, CEO	Treg Nobel Prize Forum Planner: Bin Li, Ph.D., Shanghai Institute of Immunology, Senior Investigator & Associate Director 15:00-15:05 Opening Remarks Speaker: Bin Li, Ph.D., Shanghai Institute of Immunology, Senior Investigator & Associate Director 15:05-15:25 Presentation: Advances in Basic and Clinical Research of Regulatory T Cells (Treg) Speaker: Songguo Zheng, Shanghai Jiao Tong University, Chair Professor & Dean, School of Cell and Gene Therapy 15:25-15:45 Presentation: Significance of Identifying and Validating Circulating Treg fci Subtypes/States in Non-Small Cell Lung Cancer Patients Using Single-Cell Analysis Speaker: Xiangdong Wang, Fudan University Affiliated Zhongshan Hospital, Distinguished Professor 15:45-16:05 Presentation: From "Immune Balance" to "Immune Oscillation" — 2025 Nobel-Winning Treg Discoveries and Future Perspectives Speaker: Bin Li, Ph.D., Shanghai Institute of Immunology, Senior Investigator & Associate Director 16:05-16:25 Presentation: Treg Therapy — From Mechanistic Studies to Clinical Translation Speaker: Ling Lv, Xuzhou Medical University, Vice President 16:25-16:45 Presentation: Targeting Treg Cell Survival and Death — Overcoming Bottlenecks in Autoimmune and Neurodegenerative Disease Therapies Speaker: Chengyu Zou, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Principal Investigator Future Translation of Treg Research 16:45-17:05 Presentation: Clinical Translation of Nobel-Winning Projects Speaker: Mingqi Lv, Novabio Therapeutics, CEO 17:05-17:25 Presentation: To Be Confirmed Speaker: Yanjing Su, MaRiNA BioTech, Founder 17:25-18:00 Panel Discussion: Innovative Translation of Treg Research Panelists: Dr. Tony Liu, Benethera Biotechnology Co.,Ltd., COO Yanjing Su, MaRiNA BioTech, Founder Feng Yang, Blue Ocean Capital, Founder Mingqi Lv, Novabio Therapeutics, CEO	
		<div>Back to Contents</div> <div>17</div>	

BIOCHINA 2026 Global Supply Chain Innovation Forum		BIOCHINA2026 CMC Global Expansion Forum		BIOCHINA 2026 Global Technology Transfer & Compliant Manufacturing Forum	
Date		March 12th		March 13th	
09:00-11:00		Exhibition Hall Closed During Opening Ceremony		Europe & North America Market 09:00–11:00 Thermo Fisher Special Session 09:00–10:00 Trends in Biopharmaceutical Global Expansion – From R&D to Manufacturing 10:00–11:00 Presentation: Regulatory Submission and Market Entry Strategies Based on China, US, and EU Guidelines <ul style="list-style-type: none"> Raw Material Selection Building Domestic Manufacturing Quality Systems Considerations in Clinical Trial Design and Other Aspects 	
11:00-12:00		Lunch & Networking		Lunch & Networking	
12:00-14:00		Global Supply Chain Development 12:00–12:20 Presentation: Challenges of High-Frequency International Expansion on Supply Chain Development Speaker: Fangfang Ma, Henlius Biotech, Supply Chain Executive Director 12:20–12:40 Presentation: Design and Build the Right Supply Chain for Global Success Speaker: Dr.Frank Binder, GSCA, Global Supply Chain Advisors 12:40–13:00 Presentation: International Cold Chain and Transportation Services 13:00–14:00 Panel Discussion: Global Supply Chain Strategies Panelists: Rong Tan, Novartis, Supply Chain Director Fangfang Ma, Henlius Biotech, Supply Chain Executive Director		CMC Global Expansion 12:00–13:00 Panel Discussion: Product Global Expansion Planning and Process Considerations Moderator: Shengchang Xu, Henlius Biotech, SVP&CTO Panelist: Hua Xie, Duoning Biotech, SVP Xiaoming Yang, RemeGen, CMO Kai Gao, Asymchem Laboratories, CTO Weichang Zhou, MediLink Therapeutics, CTO 13:00–13:20 Presentation: On-Site Inspections and Case Sharing of Biologics by FDA, EMA, and PIC/S Speaker: Shi Bai, TopAilance, Suzhou UnionBiopharm Biosciences Co.,Ltd., VP of Quality 13:20–13:40 Presentation: Key Focus Areas of UAE Inspectors in Antibody Drug Manufacturing Inspections Speaker: Bing Tu, Zhejiang Provincial Drug Inspection Center, Biological Products Inspector 13:40–14:00 Presentation: Capturing Global Growth Markets: Registration Strategies and Implementation Pathways for Biologics along the “Belt and Road” Speaker: Chengde Zheng, Mabwell (Shanghai) Bioscience, RA head	
14:00-15:00		Networking & Events		Networking & Events	
15:00-18:00		Local Supply Chain Development 15:00–15:20 Presentation: CDMO Supply Chain Development and Management for Cell & Gene Therapy Speaker: Hui Chen, Porton Advanced, CEO & Porton Pharma, CFO 15:20–15:40 Presentation: Establishing a Biologics Supply Chain System Speaker: Yilong Xie, Chia Tai Tianqing, Supply Chain Director 15:40–16:00 Presentation: Supply Chain Construction and Management Challenges in CXO Companies Speaker: Jie Shang, Chime Biologics, Supply Chain Director 16:00–16:20 Presentation: Supplier Management and Supply Chain Organizational Collaboration Strategies Speaker: Jinxi jia, Remegen.cn, Supply Chain Management Department, Executive Director 16:20–17:00 Panel Discussion: Innovations in Supply Chain Management Panelists: Haixia Gao, Shanghai Cell Therapy Group, Senior Director of Supply Chain Jinxi jia, Remegen.cn, Supply Chain Management Department, Executive Director Yilong Xie, Chia Tai Tianqing, Supply Chain Director Xunbing Yan, Revvity, Head of Reagents Procurement, China Case Studies in Supply Chain Management 17:00–17:20 Presentation: Laboratory Reagents and Consumables Procurement Strategies Speaker: Yanting Tong, Junshi Biosciences, Senior Purchasing Manager 17:20–17:40 Presentation: Supplier Performance Management Across All Categories Speaker: Hailong Zhang, Juventas Cell Therapy, Senior Manager, Strategic Sourcing 17:40–18:00 Presentation: Localization of Key Materials in Import Transfer Projects Speaker: Xunbing Yan, Revvity, Head of Reagents Procurement, China		CMC Global Expansion – Panel Discussion 15:00–16:00 Panel Discussion: Quality Systems and Global Compliance Moderator: Ruliang Zhang, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Senior VP and Deputy GM Panelist: Dongming Wang, Innovent Biologics, Senior Vice President Global Regulatory Submission 16:00–16:20 Presentation: IND-Stage Regulatory Submission Strategies for China, US, and EU Markets Speaker: Na Xu, Essex Bio-Technology Ltd., AVP & Head of Regulatory Affairs 16:20–16:40 Presentation: Common Regulatory Recognitions and Accelerated Programs in Drug Development for China and the US Speaker: Andy Yang, Elpisience, RA Head, Director 16:40–17:00 Presentation: Post-Approval Pharmaceutical Change Management for Biologics in Europe and the US 17:00–18:00 Panel Discussion: Domestic and International Pharmaceutical Regulatory Submission and Change Management Panelist: Jianwen Li, SinoCellTech, Head of Regulatory Affairs	
				Technology Transfer and Compliant Manufacturing for Global Expansion Projects 09:00–09:20 Presentation: Elevating Quality and Compliance Standards: Operational Excellence through the Synergy of GMP and GDP Regulatory Intelligence Speaker: Dr Dinesh Khokal, BeOne Medicines Singapore, Global Director, GxP Surveillance & External Affairs, Global Quality Management Systems 09:20–09:40 Presentation: Topic TBC Speaker: Bo Wang, Johnson & Johnson, Senior Manager, Clinical Supply Chain Quality 09:40–10:00 Presentation: Brief Discussion on Drug Serialization for Overseas Markets Speaker: Yu Jiang, Suzhou UnionBiopharm Biosciences Co.,Ltd., DP Director 10:00–11:00 Panel Discussion: Early-Stage Technology Transfer Planning in Project Development Panelist: Feng Hou, Qilu Pharmaceutical, Technical Operations Director	
				Regulatory Submission and Inspection 12:00–12:20 Presentation: INVIMA GMP Audit Process and Key Considerations for Biologics Export to Colombia Speaker: Hu Dai, Jiangsu T-mab Biopharmaceutical Co., Ltd, Head of quality &QP 12:20–12:40 Presentation: On-Site Inspection Preparedness for Antibody Drugs Speaker: Shiming Yang, Bubu Biopharmaceutical, Production Director 12:40–13:00 Presentation: Data Integrity and Case Studies in Domestic/International Manufacturing Inspections Speaker: John Loeng, GeneScience Pharmaceuticals, Executive Director, Clinical Quality Assurance 13:00–14:00 Panel Discussion: CMC System Establishment and Domestic/International Inspection for Large-Scale Manufacturing Moderator: Jianjun Luo, WuXi XDC, VP & Head of Conjugated Formulation Development and Manufacturing Panelist: Ding Liu, Qilu BioPharma, Deputy General Manager Haijun Wu, Alphamab Oncology, SVP Juping Shen, CANbridge Pharmaceuticals, SVP Jianjun Luo, WuXi XDC, VP & Head of Conjugate Formulation Development and Manufacturing	
				Commercial Manufacturing 14:00–14:20 Presentation: Challenges and Considerations Before Commercial Manufacturing from a Process Validation Perspective Speaker: An Wang, Shanghai Langrun Mabwell Biomedical Technology Co., Ltd, Quality Head 14:20–14:40 Presentation: Biologics Process Validation under the QBD Concept Speaker: Junwei Li, Lunan Pharmaceutical, Production Director 14:40–15:00 Presentation: Future Manufacturing – Smart Biopharmaceutical Factories 15:00–15:20 Presentation: Multi-Product Shared-Line Manufacturing 15:20–15:40 Presentation: Raw Materials and Supply Chain Management in Commercial Manufacturing 15:40–16:00 Q&A / Discussion	
				<div>Back to Contents</div> <div>18</div>	

BIOCHINA2026 Innovative Process Technology Forum			
Date	March 12th	March 13th	March 14th
09:00-11:00	Process Development & PPQ 10:00-11:00 Panel Discussion: Antibody Process Development and PPQ Process Validation Moderator: Xianli Su, Qilu Pharmaceutical, Lead of Manufacturing Science and Technology Panelists: Zhiqiang Chen, D3 Bio, Head of CMC Bingqing Wang, TJ Biopharma, Director of Technical Operations Yefei Wang, Gmax Biopharm LLC., Vice President Xin Xin, MediLink Therapeutics, Executive Director of CMC Operations Management Guiling Jia, Chengqi Zhizao (Beijing) Technology Co., Ltd., Founder & CEO	Title Sponsor: Sunresin New Materials Co., Ltd. Purification Processes and Digital Intelligence Empowerment 09:00-09:20 Presentation: Chromatography Resins Speaker: Qiang Chen, DanausGT BioTechnology, CTO 09:20-09:40 Presentation: Topic TBD Speaker: Sunresin New Materials Co., Ltd. 09:40-10:00 Presentation: Empowering Continuous Biopharmaceutical Manufacturing with Digital Intelligence Speaker: Dongqiang Lin, Zhejiang University, Professor of College of Chemical and Biological Engineering 10:00-11:00 Panel Discussion: How Artificial Intelligence Drives Innovation in Biopharmaceutical Downstream Processes: Case Studies, Challenges, and Future Directions Moderator: Yan Fang, Qilu Pharmaceutical Company, Senior Director Panelists: Dr. Dongmei Han, Henlius, General Manager of Process Development Dongqiang Lin, College of Chemical and Biological Engineering, Zhejiang University, Professor	ADC Process Development 09:00-09:20 Presentation: CMC Research on Bispecific ADCs Speaker: Xiaojing Gong, InnolakeBio, Associate Director, CMC 09:20-09:40 Presentation: Early-Stage Process Development of ADCs: Studies and Key Considerations Speaker: Dr. Wenjie Shao, Gan&Lee Pharmaceutical Inc., Executive director 09:40-10:00 Presentation: ADC Process Characterization and Process Validation Speaker: Yun He, WuXi XDC 10:00-11:00 Panel Discussion: Implementation of ADC CMC Development Strategies and Globalization Pathways Panelists: Min Zhao, Phrontline Biopharma, VP Jianxin Chen, Zencore Biologics, CEO Jianqiu Mi, Nanomicro Technology, Deputy General Manager
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	ADC Quality and Regulatory Submission 12:00-12:20 Presentation: Key Considerations for ADC Regulatory Submissions Speaker: Xuejing Yao, Shanghai Pharmaceuticals, Head of ADC Early Research, Central Research Institute & General Manager, Quality Department 12:20-12:40 Presentation: Quality Research of ADC Drugs Speaker: Lingrui Li, Lepu Biopharma, Associate Director, Analytics 12:40-13:00 Presentation: Strategies and Case Studies for Complex Molecule Quality Analysis Speaker: Wen Li, XDC, Associate Director 13:00-14:00 Agilent Special Session 13:00-13:30 Presentation: Application and Progress of Multi-Platform Characterization for ADCs Speaker: Min Xia, Agilent, Biopharmaceutical Technology Specialist 13:30-14:00 Presentation: High-Throughput Capillary Electrophoresis Enabling Rapid Development of Next-Generation Antibody Drugs Speaker: Hao Chen, Agilent, Genomics Technology Specialist	Antibody CMC Development and Management Session 12:00-12:20 Presentation: Challenges and Strategy Adjustments in Process Development for Different Types of Large Molecule Drugs Speaker: Jingjing Lin, Livzon Mabpharm, Director, Process Development 12:20-12:40 Presentation: Considerations in Upstream Process Development for Antibody Drugs Speaker: Yanwen Bao, Halobio, Deputy Director 12:40-13:00 Presentation: Antibody Process Characterization Speaker: Chao Yu, Shanghai Pharmaceuticals, Production Director 13:00-14:00 Lisure Technology Special Session 13:00-13:50 Presentation: LetsGo3.1 (M++): Direct Application – One-Stop Downstream Process Solution for Clinical Production Speaker: Zuwei Jin, Lisure (USA), General Manager 13:50-14:00 Q&A	Analytical Testing and Quality Management 12:00-12:40 Panel Discussion: Challenges and Breakthroughs in Quality Control and Analytical Testing of Biologics: From Pharmacopoeial Standards to End-to-End Quality Control Across R&D and Manufacturing Panelists: Chen Gang, Shanghai Institute for Drug Control (SIFDC), Chief Pharmacist Fei Wang, Shanghai Applied Protein Technology Co., Ltd., Technical Director 13:00-13:20 Presentation: Overview of Updates and Revisions to Biological Analytical Methods in the 2025 Edition of the Chinese Pharmacopoeia (Volume III) Speaker: Chen Gang, Shanghai Institute for Drug Control (SIFDC), Chief Pharmacist 13:20-13:40 Presentation: Establishment and Implementation of Quality Management Systems Speaker: Dehua Shen, Zai Lab, Deputy Director of Quality 13:40-14:00 Presentation: Process Residuals: Quality Control and Analytical Strategies Speaker: Lin Bian, Genrix Biopharmaceutical, Associate Director, Quality Control 14:00-14:20 Presentation: From Process to Product: Quality Control and Analytical Approaches Across MSC-sEV Therapeutic Development Speaker: Shuangshuang Yang, Shandong Qilu Cell Therapy Engineering Technology Co., Ltd., R&D Project Manager 14:20-14:40 Presentation: Oligonucleotide Drugs Speaker: Yanshan Lu, Youjia (Hangzhou) Biomedical Technology Co., Ltd., Deputy General Manager / Quality Director 14:40-15:00 Presentation: CAR-T / Gene Therapy 15:00-15:20 Presentation: Peptides 15:20-15:40 Presentation: Small Molecules 15:40-16:00 Q&A / Discussion
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Cell Line Development & Construction 15:00-15:20 Presentation: Antibody Expression Vectors / CHO High-Expression Cell Line Construction Speaker: Dr. Zhiwei Song, Nexa Biologics, Singapore, CSO 15:20-15:40 Presentation: Flexible and Rapid Cell Line Development Platform Applicable to Multiple Protein Types Speaker: Zichen Qian, RemeGen, Director of Process Development 15:40-16:00 Presentation: Toward high-antibody-producing CHO cell lines: from random to targeted integration technologies Speaker: Yuansheng Yang, Bioprocessing Technology Institute, Senior Principal Scientist 16:00-17:00 Swiss Blo Biologics Special Session 16:00-16:45 Presentation: Engineering Efficiency: Advanced Bioreactor Concepts for Sustainable Bioprocessing Speaker: Kurt Eyer, Bioengineering AG, Head of Innovation 16:45-17:00 Q&A 17:00-18:00 Panel Discussion: Construction and Culture Optimization of High-Producing Bispecific/Multispecific Antibody Cell Lines Moderator: Xi Chen, Qilu Pharmaceutical, Director, Cell Engineering Speaker: Dr Song Zhiwei, NexaBiologics, Singapore, CSO Yuansheng Yang, Bioprocessing Technology Institute, Senior Principal Scientist Zichen Qian, RemeGen, Director of Process Development	Sponsored Session: Cytiva Downstream Process Development for Antibodies Planner: Hao Li, Hutchison Whampoa, VP 15:00-15:20 Presentation: Process Design and Robust Scale-Up for “Abnormal Yield” Projects Speaker: Weifeng Chen, Mabgen Biotech, Senior Manager, Purification Process Development 15:20-15:40 Presentation: Strategies for Efficient Operation of Antibody Purification Processes at 10,000-L Scale Speaker: Weiwei Hu, Chia Tai Tianqing, Head of Manufacturing 15:40-16:00 Presentation: Application of In Silico Modeling in Downstream Chromatography Process Development Speaker: Zijun Su, BeOne Medicines, Downstream Process Manager 16:00-16:20 Presentation: Application of AI PSO Algorithm in Downstream Process Development Speaker: Yuwen Zhu, BeOne Medicines, Senior Scientist 16:20-16:40 Presentation: Topic TBC Speaker: Cytiva 16:40-17:40 Panel Discussion: CMC Development and Lifecycle Management of Antibody Drugs under Global Compliance Moderator: Hao Li, Hutchison Whampoa Limited, VP Panelists: KarenTwu, Hutchmed, VP Guanhua Wang, Elpiscience Biopharma, CMC VP	

BIOCHINA2026 Small Molecule Drug Innovation Forum			BIOCHINA 2026 AI for Science Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Opening Panel Discussion 10:00–11:00 Panel Discussion: Innovation Breakthroughs in Small-Molecule Drugs from a Researcher's Perspective Moderator: Li Chen, Hua Medicine (Shanghai) Ltd., CEO Panelists: Donghui Qin, Phaeno Therapeutics, Chairman & CEO John Yu, CGeneTech(Suzhou,China)Co.,Ltd., CEO Yuanwei Chen, Hinova Pharmaceuticals Founder & Chairman Yusheng Wu, Ph.D., TYK Medicines, Inc. Chairman of Board & CEO Qun Dang, Genuine Biotech, Executive Director, President & Chief Business Officer (CBO)	Clinical Indication Development – Oncology Drugs 09:00–09:40 09:00–09:40 Panel Discussion: Oncology Drug Development Moderator: Li Zeng, Jine Medical Science And Technology (Shanghai) Co., Ltd., CEO Panelists: Fugen Li, Translational Medicine HaiHe Pharmaceuticals Inc., SVP Song Liu, SynRx Therapeutics, CEO 09:40–10:00 Presentation: Development of Second-Generation PARP Inhibitors Speaker: Dr. Li Wang, Xuanzhu Biopharmaceutical Co., Ltd., CMO, Deputy General Manager 10:00–10:20 Presentation: Enabling Patient Access to Targeted Therapies with Rapid and Accessible NGS CDx Solution Speaker: Daisy Sun, Thermo Fisher Scientific, Diagnostics Partnering China Lead 10:20–10:40 Presentation: Developing AMX3009: Optimal Therapy for Non-Classic PACC-Mutant Lung Cancer Speaker: Dr. Jian Hong, Arromax Pharmaceutical, General Manager & Co-Founder 10:40–11:00 Presentation: Top 25 Translational Medicine Targets in 2025 (Early-Stage Drug Development) Speaker: Xihong Hu, PharmCube, Senior Researcher	Basic Research and Core Technology Integration 09:00–09:30 Presentation: Multimodal Biological Foundation Models for Disease Mechanism Exploration (Title TBD) Speaker: Luyi Tian, Guangzhou Laboratory, Researcher 09:30–10:00 Presentation: Digital Cell Foundation Models Empowering Drug Target Discovery Speaker: Xin Li, Institute of Zoology, Chinese Academy of Sciences & Beijing Institute for Stem Cell and Regenerative Medicine, Joint-appointed Researcher 10:00–10:30 Presentation: Title TBD 10:30–11:00 Presentation: What Is Still Missing in Biomedical AI? From “Data Volume” to “Data Usability” Speaker: Shengce Tao, Shanghai Institute of Systems Biomedicine, Shanghai Jiao Tong University, Vice Dean & Professor
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Innovative Drug Development & Global Expansion 12:00–13:00 Panel Discussion: Technology and Market-Driven Diversified Collaborations in Small Molecule Innovative Drugs Panelists: Xiang Li, Xellsmart, CEO Chun Liang, Enkang Pharmaceuticals, Professor, Hong Kong University of Science and Technology & Founder & CSO, Enkang Pharmaceuticals Jane Wang, Salubris Pharmaceuticals, CSO Dr. Liping Liu, HighTide, Founder & CEO 13:00–13:20 Presentation: Breakthrough and Renewal — Innovative Clinical Development Strategies for Small Molecule Drugs Speaker: Sumei Liu, Hengrui Pharmaceuticals, Senior Medical Director 13:20–14:00 Panel Discussion: Innovative Development of Small-Molecule Drugs from a Clinical Perspective Panelists: Liu Yang, Allorion Therapeutics, VP, Clinical Development Yilin Li, Zhengxiang Pharmaceutical, CMO Jiahong Zhao, CGeneTech(Suzhou,China)Co.,Ltd., CMO Xiaoning Guo, HaiHe Pharmaceutical, CMO	Clinical Indication Development – Multi-Indication 12:00–12:20 Presentation: Preclinical Exploration of FIC Three-Target Small Molecule Innovative Drugs in Autoimmune Diseases Speaker: Xiaohong Yu, Fosun Pharma and Chairman of Novaonco Co., Ltd., Co-CSO 12:20–13:00 Panel Discussion: Case Sharing on Autoimmune Drug Development Panelists: Yang Song, Hygtia Therapeutics, Fosun Pharma Global R&D, Vice President, Head of I&I, CEO Shuihua Zhang, NewDEL Biotech, Deputy General Manager Karen Liu, Ph.D., 3E Bioventures Capital, Founding Partner Thermo Fisher 13:00–13:20 Presentation: Ifogrel (CG-0255) Development Case: Best-in-Class Anti-Platelet Drug Addressing Cardiovascular and Cerebrovascular Clinical Gaps Speaker: XiaoWu Chen, Shanghai CureGene Pharmaceutical Co., Vice President, Chemistry 13:20–13:40 Presentation: Antiviral Drug Development Speaker: Hejun Lv, Ark Biopharmaceutical, CSO 13:40–14:00 Presentation: TBC Speaker: Lei Li, Jiayue Pharmaceutical, Deputy General Manager, Innovative Development & External Collaboration	Drug Discovery and Clinical Translation Session 12:00–12:30 Presentation: AI-driven Small Molecule Generation Algorithms and Precision Drug Design (Title TBD) Speaker: Hongming Chen, Guangzhou Laboratory, Researcher 12:30–13:00 Presentation: Key Technologies for Original Nucleic Acid Drugs and Clinical Translation Research (Title TBC) Speaker: Zhihao Han, China Pharmaceutical University, Associate Researcher 13:00–13:30 Presentation
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Breakthroughs and Challenges in “Undruggable” Targets 15:00–16:00 Ice Bioscience Special Session 15:00–15:30 Presentation: Dual Payload ADC (Tentative) Speaker: Li Li, Ice Bioscience, VP 15:30–16:00 Presentation: TBC Speaker: Xiaojian Wang, Ice Bioscience, Senior Director Planner: Lihui Zou, Degron Therapeutics, CEO 16:00–17:00 Panel Discussion: Overcoming the “Undruggable” Challenge Panelists: Lihui Zou, Degron Therapeutics, CEO WeiWen Ying, Ranok Therapeutics(Hangzhou) Co., Ltd., CEO Xinghua Hu, Rapafusyn, CEO LI XING, LexBio Therapeutics, CEO 17:00-17:20 Presentation: Prospecting for the Undruggable TNFR1 Antagonist Speaker: Yuan Liu, University of Pittsburgh, Associate Professor of Medicine Molecular Glue Session 17:20–17:40 Presentation: RapaGlues—A Non-degrading Molecular Glue Platform for Undruggable Disease Targets Speaker: Xinghua Hu, Rapafusyn, CEO 17:40–18:00 Presentation: First-In-Class Molecular Glue Degraders Undruggable Disease Targets Enabled by GlueXplorer Platform Speaker: Hao Dou, Degron Therapeutics, Director	Clinical Indication Development – CNS 15:00–15:20 Presentation: Drug Development Efforts Targeting Depression and Alzheimer's Disease Speaker: Yelin Chen, Chinese Academy of Sciences, Principal investigator, Interdisciplinary Research Center on Biology and Chemistry 15:20–15:40 Presentation: Innovative Breakthroughs in CNS Drug Development Speaker: Qi Zhong, Pfizer China R&D Center, Associate Director, Clinical Development 15:40–16:20 Panel Discussion: CNS Drug Development Panelists: Chao Zhang, NeuShen Therapeutics, COO Qi Zhong, Pfizer China R&D Center, Associate Director, Clinical Development Li Yan, Ice Bioscience, Chairman Yishan Sun, Ignis Therapeutics, Vice President of Biology CMC & Quality Control 16:20–17:20 Executive Panel Discussion: Innovative Breakthroughs in Small-Molecule Drug Development Panelists: Jingrong Li, GenFleet Therapeutics, CTO Wenge Zhong, Qilu Regor Therapeutics, CTO 17:20–18:00 Panel Discussion: Further Optimization of CMC and Quality Systems in Mature Platforms Panelists: Shun Xiao, Ascentage Pharma, Senior Director, Analytics & Quality Control Kunlin Wang, Allorion Therapeutics, Senior Scientist, CMC JinYue Tu, Suzhou Genhouse Bio Co., Ltd., CMC Director	
			Back to Contents
			20

BIOCHINA 2026 Oligonucleotide Drug Innovative Development Forum		BIOCHINA 2026 Peptide Drugs Innovative Development Forum		BIOCHINA 2026 Nucleic Acid Drug Innovative Development Forum	
Date	March 12th	March 13th		March 14th	
09:00-11:00	<p>Opening Panel Discussion 10:00–11:00 Panel Discussion: Innovative Collaborative Development of Oligonucleotide Drugs Moderator: Bin Shi, BridGene Biosciences, Partner Panelists: Xuefeng Zhang, ChainGen Bio, Co-Founder & COO Honghui Pan, Sirnaomics, CEO Xiaoye Su, CSPC Pharmaceutical, President, Research Institute Dr. Qunsheng Ji, Sirius Therapeutics, CEO</p>	<p>Executive Panel Discussion 09:00–09:20 Presentation: Global GLP-1 Landscape Analysis in Obesity Speaker: Jie Dai, PharmaCube, Senior Researcher 09:20–10:00 Panel Discussion: Innovation in Next-Generation Peptide Drugs Panelists: WenXin Song, Shanghai Minwei Biotechnology Co.,LTD, Deputy general manager Xiao Zhang, Syneron Bio, CEO Bing Wang, Micot Pharmaceutical, CEO</p> <p>Oral Cyclic Peptides 10:00–10:20 Presentation: Oral Cyclic Peptide: A New Modality? Speaker: Chenguang Yuan, Sungeneing Biological, Co-Founder & CSO 10:20–10:40 Presentation: Structural Modification and Screening Methods Innovative Target Development Case Sharing 10:40–11:00 Presentation: RapaGlues– A Bridge between Macrocyclic Peptides and Molecular Glues for Interrogating Hard to Drug Targets Speaker: Rick Ewing, Rapafusyn, VP Head of Chemistry</p>		<p>mRNA Cancer Vaccines 09:00–09:40 Panel Discussion: Future Development of mRNA Cancer Vaccines Moderator: Chenyang Wu, Pivotal BioVenture Partners, Investment Director Panelists: Rongkuan Hu, Starna Therapeutics, Founder & CEO Changyun Xiong, Junjian Biotechnology, CEO Aimin Hui, MD, PhD, EnCureGen Pharma, Founder, Chair & CEO 09:40–10:00 Presentation: triVac Universal Modification Platform Enabling Cancer Vaccine Development Speaker: Dr. Shiyu Li, Tricision Biotherapeutics, Inc, Co-Founder & CTO 10:00–10:20 Presentation: Clinical Exploration and Key Breakthroughs in mRNA Therapeutic Cancer Vaccines Speaker: Xiangrong Song, Ph.D., WestGene Biopharma, CEO & Scientific Co-Founder 10:20–10:40 Presentation: Advancing mRNA Vaccines and Therapies: Collaboration, Science, and Impact Speaker: Roberta Duncan 10:40–11:00 Presentation: TBC Speaker: Shan Cen, RinuaGene Biotechnology, CSO</p>	
11:00-12:00	Lunch & Networking	Lunch & Networking		Lunch & Networking	
12:00-14:00	<p>Oligonucleotide Drug Clinical Development Case Sharing Planner: Dong You, Executive VP of Clinical R&D, ViaZen 12:00–12:20 Presentation: Analysis of Clinical Development Strategies for siRNA Drugs and Overview of Clinical Data Speaker: Dr. Dong You, Visirna Biotech, EVP 12:20–12:40 Presentation: Clinical Development and Progress of siRNA Drugs in Cardiovascular/Metabolic Diseases Speaker: Lihang Qi, Visirna Therapeutics, MD, Medical 12:40–13:00 Presentation: Clinical Development and Progress of siRNA Drugs in Non-Cardiovascular/Metabolic Diseases Speaker: Jing Hao, Visirna Therapeutics, MD, Medical Clinical Indication Exploration of Oligonucleotide Drugs 13:00–13:20 Presentation: Anti-Tumor Oligonucleotide Drug HC016 Speaker: Jun Bai, Haichang Biotech, Head of Small Nucleic Acid Department 13:20–13:40 Presentation: IgA Nephropathy 13:40–14:00 Presentation: Functional Cure Indication for Clinical Hepatitis B Speaker: Zhongnan Xu, Siranbio, VP</p>	<p>Phase III Clinical Project Development 12:00–12:20 Presentation: Diabetes Project Development Speaker: Wei Chen, Gan & Lee Pharmaceuticals, Chairman, President & CEO 12:20–12:40 Presentation: Metabolic Diseases 12:40–13:00 Presentation: Clinical Development Strategies for MASH Drugs Speaker: Lin Zhang, Shanghai Benemae Pharmaceutical Corporation, Medical department Head GLP-1 Development Case Sharing 13:00–13:20 Presentation: GLP-1 Clinical Development Strategies and Value Redefinition Speaker: JiaoWei Lu, Innovent, Clinical Development Sr. Director 13:20–13:40 Presentation: Development of Anti-obesity Peptide Drugs Speaker: Nan Zheng, Shenzhen Bay Laboratory, Researcher at the Conversion Innovation Center 13:40–14:00 Presentation: Development Strategies for Ultra-Long-Acting Weight-Loss Drugs Speaker: Yuanyuan Zhang, Peptide Biomedical, Co-Founder, SVP & Head of R&D</p>		<p>Potential mRNA Development Based on Cell-Targeting Technologies 12:00–12:20 Presentation: Development and Application Progress of Base Editing Technologies for Targeted mRNA Speaker: Rong Xin, Shixi Biologics, CEO 12:20–12:40 Presentation: Fat-Targeted Development Research Speaker: Sunny Huang, Axter Therapeutics, VP 12:40–13:00 Presentation: Research on mRNA Delivery Systems and Applications Speaker: Jianbin Tang, Zhejiang University, Professor, School of Chemical Engineering and Biotechnology 13:00–13:20 Presentation: Lipid Carrier Design and Its Exploration in RNA Drug Development Speaker: Xueqing Zhang, Rongcan Biotech, CSO & Professor, School of Pharmaceutical Sciences, Shanghai Jiao Tong University</p> <p>Circular mRNA Technology Innovation 13:20–13:40 Presentation: Circular RNA Drug Development and Latest Progress Speaker: Dr. Chenxiang Tang, CirCode Biomed, CEO 13:40–14:00 Presentation: Applications of Circular RNA in Oncology, Autoimmune Diseases, and Regenerative Medicine Speaker: Chijian Zuo, Suzhou CureMed Biopharma Technology.Co.,Ltd, Vice President 14:00–14:20 Presentation: Process Optimization of Circular RNA Speaker: Jingyuan Wu, CirCode, Director, CMC 14:20–14:40 Presentation: Overcoming CMC Technical Challenges Speaker: Shaoyun Qi, Abogen Biosciences, Head of Circular RNA Platform</p> <p>RNA Delivery & Future Applications 14:40–15:00 Presentation: TBC Speaker: Dr. Sean Sample, Acuitas Therapeutics Inc., VP, Preclinical 15:00–15:40 Panel Discussion: Breakthroughs in Nucleic Acid Drug CMC Processes and Future Delivery Innovations Panelist: Dr. Yun Yang, Shanghai CirCode Biomed, Co-Founder, Chairman & CTO Youru Wang, Ningbo Junjian Biotechnology Co., Ltd., CSO Xueqing Zhang, Rongcan Biotech, CSO & Professor, School of Pharmaceutical Sciences, Shanghai Jiao Tong University</p>	
14:00-15:00	Networking & Events	Networking & Events		Networking & Events	
15:00-18:00	<p>Oligonucleotide Drug Technology Development & CMC Strategies 15:00–15:20 Presentation: Progress in Diabetes and Ophthalmology Small Nucleic Acid Drug Development at Anlong Bio Speaker: Chunlin Zhao, Ph.D, AnlongBio/AnlongMed, Founder 15:20–16:00 Panel Discussion: Oligonucleotide Drug Development and Industrialization Challenges Moderator: Peter Zhang, Suzhou GenePharma Co., Ltd, Chairman & CSO Panelists: Yi Huang, Chengdu Goworld Pharmaceutical Co., Ltd., General Manager of the Innovative Drug Division Dr. Jingqiao Wan, Leaderna Therapeutics Ltd., Chairman & CEO Sheng Zhou, Lisure Science, Deputy General Manager Huifang Dong, Porton Pharma Solutions, Head of Large Molecule Drug R&D and Manufacturing Center Chengjiang Zhao, Youjia Bio, Director of Youjia Institute for RNAi therapeutics Non-Liver Targeted Delivery Research 16:00–16:20 Presentation: Expanding RNAi Therapies Beyond the Liver – Unlocking the Full Potential of RNAi Delivery Speaker: Jiehua Zhou, Leaderna Therapeutics, Ltd., Co-Founder & CSO 16:20–16:40 Presentation: Development and Progress of Small Interfering Nucleic Acid Nanoparticles for Local Fat Reduction Speaker: Weiwei Tian, Sirnaomics, General Manager 16:40–17:00 Presentation: TBC Speaker: Yun Wu, Yunho Biotech, Co-Founder & Chief Scientific Officer (CSO) 17:00–17:20 Presentation: Small Nucleic Acid Drugs Will Impact the Fat Reduction and Muscle Building Market Speaker: Lorenzo Xie, Ph.D., Ractigen Therapeutics, CSO 17:20–17:40 Research Progress on Non-Liver Targeted Obesity Small Nucleic Acid Drugs Speaker: Yanhui Wang, Innovent Biologics, Associate Director, Nucleic Acid Therapeutics & Head of siRNA Drug Discovery 17:40–18:00 Q&A / Discussion</p>	<p>Case Studies in GLP-1 Drug Development 15:00–16:00 Panel Discussion: Multi-Indication Exploration – From AD Failure to MASH Breakthrough Moderator: Xiaogang Hui, Innogen Pharmaceutical, Medical Director Panelists: Dr. Meng Liu, Hasten Biopharmaceutical, Vice President, Head of Medical Tongying Wang, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Technical Director Shanghai Medicilon Inc. Meng Qiao, Pfizer, Director Xiancheng Zeng, Medicilon, VP of Preclinical Research JiaoWei Lu, Innovent, Clinical Development Sr. Director Planner: Dr. ZiFei Yuan, Gan & Lee Pharmaceuticals, VP & CTO Peptide Synthesis Process & Production Key Points 16:00–16:20 Presentation: CMC Development Strategies and Core Considerations for Biocomposite Formulations Speaker: Dr. Zifei Yuan, Gan & Lee Pharmaceuticals, VP & CTO 16:20–16:40 Presentation: Process Optimization and Key Technological Breakthroughs for Industrialization Speaker: Fengyun Yang, Gan & Lee Pharmaceuticals, Director, Formulation Development 16:40–17:00 Presentation: Key Points in Peptide Drug Production Optimization Speaker: Dr. Wancai Xing, Gan & Lee Pharmaceuticals, Director of the R&D Analysis Department Peptide Commercial Production Planning 17:00–17:20 Presentation: Full Lifecycle CMC Development Strategies and Risk Management for Peptide Drugs Speaker: Vincent Qu, Shenzhen ScienCare Pharmaceutical Co., Ltd., CTO 17:20–18:00 Panel Discussion: Overcoming Challenges in Large-Scale Peptide Production and Process Scale-Up Panelists: Dr. John Fan, Micot Pharmaceutical Technology Co., VP of CMC Dongdong Huo, Sepax Technologies, Director of Applications Peng Zhai, Peptide Biomedical, Co-Founder & SVP</p>			
				<div>Back to Contents</div>	
				21	

BIOCHINA 2026 AI Innovation Forum		BIOCHINA 2026 XDC Drug Innovative Development Forum	
Date	March 12th	March 13th	March 14th
09:00-11:00		Global ADC Development and Collaboration 09:00–10:00 Panel Discussion: Global Strategy and Collaboration in ADC Drug Development Moderator: Hu Li, Ph.D., ERVC, Venture Partner Panelists: Ziping Wei, Bridge Biotherapeutics (Hangzhou) Co., Ltd., Co-Founder, Chairman, & CEO Ziye Sui, Lepu Biopharma Co., Ltd., CEO Yongxin Zhao, Hangzhou DAC Biotechnology Co., Ltd., Founder & CEO Jingcai Li, WuXi XDC, CEO Jiaqiang Cai, MediLink Therapeutics, Co-Founder & Co-CEO & CSO 10:00–11:00 XDC Drug R&D – Ruizhi Pharma Special Session 10:00–10:30 Presentation: XDC – Chemistry Focus Speaker: Yong Sui, Chempartner Pharmatech, Associate Director, Chemistry R&D 10:30–11:00 Presentation: XDC – Biology Focus Speaker: Guihe Liang, Chempartner Pharmatech, Director, XDC & Biologics R&D	XDC: From Preclinical to Clinical Focus 09:00–10:00 Panel Discussion: From Preclinical to Clinical Stages: Developability Assessment and Clinical Strategy Optimization for XDCs Panelists: Xuebin Liu, Inxmed, Senior Vice President (SVP) Dr. Zhaorong Chen, Doma Biopharmaceutical (Suzhou) Co., Ltd., CMO Mo Xu, Yahong Meditech, Head of Clinical Development & SVP Xingquan Ma, Chempartner Pharmatech, Co-President & Head of Chemistry BU Rang Gao, M.D., Xiling Lab, CMO 10:00–10:20 Presentation: Bridging the Gap: Leveraging AI for Precision Degradar & DAC Design on "Plug-and-Play" Scaffolds to Ensure Rapid Execution Speaker: Masahiko Hayakawa, Ubiquarion Therapeutics, Ph.D., MBA / CSO 10:20–10:40 Presentation: Challenges Across the Full Process from Preclinical Research to Clinical Trials 10:40–11:00 Presentation: Combination Therapy Strategies for XDC
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	AI-Enabled Drug Discovery and Development 12:00–13:00 Panel Discussion: Technological Breakthroughs and Practices from Target Discovery to Clinical Translation Panelists: Dr. Lipeng Lai, XtalPi, Co-Founder & CIO Yun Zhu, Yunho Biotechnology, CEO Xuan Xian, GeneScience Pharmaceutical, Director, AI Drug Discovery Institute Dr. Di Hong, Nona Biosciences, CEO Jian Zhang, Nutshell Therapeutics, Founder Lianyi Han, Ph.D., Hengrui, Head of AIDD 13:00-14:00 Tianwu Technology Special Session AI Applications in Next-Generation Innovative Protein Drug Development 13:00–13:20 Presentation: AI-Driven Innovation in Biopharmaceutical R&D Moderator: Xiaoyan Wang, 3E Bioventures Capital, Partner Speaker: Song Li, Matwings Technology, Head of AI Biopharmaceutical R&D 13:20–14:00 Panel Discussion: AI Breakthroughs: R&D and Application of Next-Generation Innovative Protein Drugs Moderator: Xiaoyan Wang, 3E Bioventures Capital, Partner Panelists: Liang Hong, Shanghai Jiao Tong University, Distinguished Professor & Chief Scientist, Matwings Technology Han Dai, Viva Biotech Holdings, Chief Innovation Officer (CINO) Zhui Chen, OTR Therapeutics, Founder & CEO	Latest ADC R&D and Clinical Progress 12:00–12:20 Presentation: Progress in Bispecific and Dual-Target ADC Research Speaker: Siyi Hu, Phrontline Biopharma, Deputy General Manager 12:20–12:40 Presentation: Bispecific Toxin ADC Development Speaker: Jiawei Lu, WuXi XDC, Head of Conjugate R&D 12:40–13:00 Presentation: Clinical Validation of Next-Generation ADC Platform Technologies Speaker: Dr. Qing Zhou, Escugen Biotechnology, Founder & CEO 13:00–13:20 Presentation: Clinical Insights of Bispecific ADCs Speaker: Dr. Zhaorong Chen, Doma Biopharmaceutical (Suzhou) Co., Ltd., CMO 13:20–13:40 Presentation: Early Clinical Development: Successes, Failures, and Lessons Learned Speaker: Rang Gao, Innovative Drug Company, CEO 13:40–14:00 Q&A / Discussion	PDC Innovation and Clinical Development 12:00–12:20 Presentation: Bi-XDC — Innovative Oncology Pipeline Targeting Unmet Needs and Clinical Progress Speaker: Ji Yang, COHERENT BIOPHARMA (SUZHOU) Co., Ltd., Clinical Operations Director 12:20–12:40 Presentation: Synergistic Effects of Dual-Target PDC Design Speaker: Jun Shao, Coherent Biopharma, CTO 12:40–13:00 Presentation: Peptide-Drug Conjugate (PDC) Delivery Strategies Speaker: Xiaoyu Zang, N1Life, CEO Conjugation Technology Focus 13:00–13:20 Presentation: Application of Novel ADC Technologies and Clinical Translation Speaker: Wei Lian, MediLink Therapeutics (Suzhou) Co., Ltd., VP of Translational Medicine 13:20–13:40 Presentation: Addressing ADC Resistance: Next-Generation ADC Platforms and Pipelines 13:40–14:00 Presentation: Oligonucleotide Conjugates (AOC/ODC) 14:00–14:20 Presentation: Protein-Conjugated Drugs (PLC) 14:20–14:40 Presentation: Radiolabeled Conjugates (RDC) 14:40–15:00 Presentation: Protein-Conjugated Drugs (PLC)
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	New Paradigms in Antibody Discovery and Development Driven by AI and Automation 15:00–16:00 Mega Technology Special Session Moderator: Fuming Zhao, MegaRobo Technologies, Director of Product Marketing 15:00–15:20 Presentation: Antibody R&D Accelerator — The Synergistic Revolution of AI and Automation Speaker: Shiqiang Liu, MegaRobo Technologies, Senior Product Manager 15:20–16:00 Panel Discussion: In the AI+ Era, How Can Companies Restructure Antibody R&D Efficiency and Barriers to Leapfrog Ahead? Moderator: Yan Zhang, MegaRobo Technologies, Co-Founder & SVP Panelists: Yuguang Wang, Toursun Symbio, Founder & CEO & Associate Professor, Shanghai Jiao Tong University Xin Guo, Shanghai Institute of Science and Intelligence, Chief Researcher Ruilian Hu, Chempartner Pharmatech, Chairman & CEO Innovative Practices in Multi-Modality Drug Development and Process Manufacturing 16:00–16:20 Presentation: From Generative AI to the Clinic: AI-Driven End-to-End Drug Discovery and Development Speaker: Jue Wang, InSilico Medicine Cayman TopCo, VP, Business 16:20–16:40 Presentation: Application Cases of AI in Peptide and Nucleic Acid Drug Development Speaker: Dr. Lipeng Lai, XtalPi, Co-Founder & CIO 16:40–17:00 Presentation: TBC Speaker: Lianyi Han, Ph.D., Hengrui, Head of AIDD 17:00–17:20 Presentation: AI-Empowered Process Manufacturing: A Case Study from GenSci Pharmaceutical Speaker: Xuan Xian, GeneScience Pharmaceutical, Director, AI Drug Discovery Institute 17:20–17:40 Presentation: AI-Enabled Biopharmaceutical Fermentation Processes Speaker: Dr. Khaled Baraka, Thoth BioSimulations, CEO & Chief Scientist 17:40–18:00 Presentation: AI-Driven Drug Production Quality and Compliance Management	Differentiated Targets and Molecular Design 15:00–16:00 Panel Discussion: Differentiated Design Driving Bispecific/Multispecific ADC Breakthroughs and Innovative Approaches in Linker-Payload Development Moderator: Yinghui Yu, Johnson & Johnson, Senior Director, Global BD Panelists: Lili Shi, GeneQuantum Healthcare, Vice President of R&D Yuhong Zhou, BlissBio, CSO Xiwu Hu, CSPC Pharmaceutical, President, Research Institute Nianhe Han, Xinma Biomedical, CSO Yangsheng Qiu, Huahai Tianheng, SVP From Oncology to Autoimmunity: ADC Clinical Pathology and Combination Therapy 16:00–16:20 Presentation: ADC Drug Development Progress in Lung Cancer Speaker: Anwen Xiong, Shanghai East Hospital, Associate Chief Physician, Associate Professor 16:20–16:40 Presentation: Computational pathology to guide use of ADCs Speaker: Dr. Hadassah Sade, AstraZeneca Computational Pathology, Managing Director 16:40–17:00 Presentation: ADC Development and Clinical Progress in Autoimmune Diseases Speaker: Dr. Xi Li, Duality Biotherapeutics, Executive Director, R&D 17:00–17:20 Presentation: TBC Speaker: Zhenwei Miao, IMBIORAY (Hangzhou) Biomedicine Co., Ltd, Chairman & CEO 17:20–17:40 Presentation: Combination Therapy of ADC and Bispecific Antibodies Speaker: Wei Li, Shanghai Dongfang Hospital, Associate Chief Physician 17:40–18:00 Q&A / Discussion	
		<div>Back to Contents</div> <div>22</div>	

BIOCHINA 2026 Antibody Drug Innovative Development Forum			BIOCHINA 2026 Regenerative Medicine & Tissue Repair Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	09:00–10:00 Panel Discussion: Focused Segment Analysis – Bispecific and Multispecific Innovative Drug Pipeline and Collaboration Strategies from a BD Perspective Moderator: Scott Liu, Ph.D., HanchorBio Inc., Founder, Chairman & CEO Panelists: ZhenHao Zhou, Chimagen Biosciences, Founder & CEO Dr. Lei Fang, Aikelian Biotech, Co-Founder, Chairman & CEO Dr. Chao Tu, Biomissile Pharmaceuticals, Co-Founder, President & CEO Dr. Pengfei Zhou, WUHAN YZY BIOPHARMA CO., LTD., Founder, Chairman & CEO CEO Zhaoyu Jin, Mingji Biopharmaceutical (Beijing) Co., CEO Jing Zhao, GemPharmatech, General Manager 10:00–11:00 ZhuHai Jinwan Special Session	Progenitor Cell Regenerative Therapy Planner: Dr. Ting Zhang, Regend Therapeutics, Founder & CEO 09:00–09:20 Presentation: Autologous Renal Progenitor Cell-Based Kidney Stem Cell Product Speaker: Yu Ma, Regend Therapeutics, VP 09:20–09:40 Presentation: Research on Tissue-Specific Adult Stem/Progenitor Cells in Chronic Diseases and Organ Repair Speaker: Wei Rao, Zhejiang University School of Medicine, Researcher 09:40–10:00 Presentation: Clinical Advances of Hepatic Progenitor Cells in Severe Liver Diseases Speaker: Zhihui Weng, Sailiwei Biotech, Deputy General Manager 10:00–10:20 Presentation: TBC Speaker: Xia Wang, Tsinghua University, Special Researcher 10:20–11:00 Panel Discussion: TBC Panelists: Dr. Ting Zhang, Regend Therapeutics, Founder & CEO Wei Rao, Zhejiang University School of Medicine, Researcher Zhihui Weng, Sailiwei Biotech, Deputy General Manager Manager Xia Wang, Tsinghua University, Special Researcher
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	12:00–13:00 Panel Discussion: Strategic Collaboration Perspective – Core Challenges and Solutions in Global Capacity Building Moderator: Youchen Chen, HBM Holdings Limited, CFO Panelists: Dr. Haibin Wang, BioRay Pharmaceutical Co., Ltd., CEO Dr. Wenzhi Tian, ImmuneOnco Biopharma, Founder, Chairman & CEO Complex Molecular Innovative Development 13:00–13:20 Presentation: Logic-Gated Technologies and Intelligent Antibody Therapeutics Speaker: Zhigang Tian, Chinese Academy of Engineering, Academician 13:20–13:40 Presentation: IL15v-NKCE: A cutting-edge NK cell engager platform for cancer treatment Speaker: Xuan Wu, EpimAb Biotherapeutics, Inc., Senior Director of Biotechnology Department 13:40–14:00 Presentation: Development of mRNA-Encoded Bispecific T-Cell Engagers (TCEs)	Antibody Drug Development and Clinical Research Based on Different Targets Planner: Yanfeng Zhang, AlaMab Therapeutics Inc., Co-Founder & CEO 12:00–12:20 Presentation: Claudin 6/9 ADC – Integrating a Unique Innovative Linker Platform with Target Biology Speaker: Yanfeng Zhang, AlaMab Therapeutics Inc., Co-Founder & CEO 12:20–12:40 Presentation: Clinical Progress Speaker: Xiugao Yang, CSPC Pharmaceutical Group Co., Ltd., Senior Medical Director 12:40–13:00 Presentation: Drug Development and Clinical Research of Innovative Targets Speaker: Sheng Tu, Hope Medicine Inc., President Antibody Drug Development and Clinical Research Across Different Indications 13:00–13:20 Presentation: Next-Generation Anti-BDCA2 mAb with Bifunctional Activity: Simultaneously Inhibiting both IFNα and B cells Speaker: Haomin Huang, 3sbio Inc., Vice president of R&D 13:20–13:40 Presentation: TBC Speaker: Yifan Zhan, Shanghai Huaota Biopharmaceutical Co., CSO, VP of Drug Discovery 13:40–14:00 Presentation: TBC Speaker: Wanmei Wang, Trinomab Biotechnology, CMO&高级副总裁	12:00–13:00 Stem Cells and Regenerative Medicine 12:00–12:20 Presentation: Breakthroughs in iPSC-Based Regenerative Transplantation Speaker: Maofa Zheng, Cellegen Biotechnology, President 12:20–12:40 Presentation: A Novel Hybrid Regenerative Medicine Product: Combining iPSC-Derived Cardiovascular Cells and Biomaterials Speaker: Kenji Kakuta, iHeart Japan, CEO 12:40–13:00 Presentation: Global First-in-Class: A Novel Multicomponent Protein Therapeutic for Reversing Neurodegenerative Diseases and Brain Injury — Cell-Free, Non-Exosomal, Industrially Standardized, Scalable, and Safe Speaker: Chen Chen, Darwincell Biotech Ltd., CBO 13:00–14:00 Regenerative Medicine and Tissue Repair 13:00–13:20 Presentation: TBC 13:20–13:40 Presentation: Exploring the Clinical Application Prospects of GHRH Analog Peptide Drugs Speaker: Hong Yu, Zhejiang University, Professor & Founder, Sinopep Allsino Bio Pharmaceutical 13:40–14:00 Presentation: Latest Clinical Progress in Fibroblast-Based Cell Therapy for Degenerative Disc Disease (Tentative) Speaker: Ming Fan, Chuiyuan Medicine, Founder & CEO 14:00–15:00 Organoids and Tissue Engineering 14:00–14:20 Presentation: Development and Application of Allogeneic Off-the-Shelf Universal Tumor-Infiltrating Lymphocytes Speaker: Hua Liu, Xinghua Bio, Founder & CSO 14:20–14:40 Presentation: Neural Regeneration and Spinal Cord Repair 14:40–15:00 Presentation: Tissue Regeneration and Trans-Germ Layer Differentiation 15:00–16:00 Panel Discussion: How Can Regenerative Medicine Technologies Be Translated into Scalable Repair Solutions?
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Bispecific Antibody Latest R&D and Clinical Progress 15:00–15:20 Presentation: Progress and Clinical Development of PD1/VEGF Bispecific Antibodies Speaker: Qiyang Lu, INSTIL BIO, CMO 15:20–15:40 Presentation: Bispecific Antibody Development, Design, and Validation in Inflammation Speaker: Tao Chen, Qyuns Therapeutics, Head of Drug Development 15:40–16:00 Presentation: Preclinical Development of T-Cell Engaging Bispecific Antibodies (TCEs) Speaker: Bing Hou, Antengene, Executive Director of Early Drug Development Trispecific / Multispecific Antibody Latest R&D and Clinical Progress 16:00–16:20 Presentation: Latest Clinical Progress of Trispecific TCEs Speaker: Yingfeng Huang, Cytocares, CEO 16:20–16:40 Presentation: Trispecific Logic-Gated TCE Development Speaker: Zuoxiang Xiao, Shimal Pharmaceutical, Chairman & Founder 16:40–17:00 Next-Generation Trispecific Antibody Development for Solid Tumor Therapy Speaker: Xianghai Cai, Novatim Immune Therapeutics (Zhejiang) Co., Ltd., VP 17:20–18:00 Panel Discussion: R&D Innovation Perspective — Breaking Through in Antibody Drug Development: From Target Discovery to Full-Spectrum Molecular Design Upgrade Moderator: Hong Ling, Leads Biolabs, CSO Panelists: Junming Ye, Shenzhen Salubris Pharmaceuticals Co., Ltd., CSO Dr. Bo Chen, China Resources Pharmaceutical Group Limited, CSO Dong Li, RemeGen Co., Ltd., General Manager, Shanghai R&D Center Hua Ying, Qilu Institute of Innovative Pharmaceutical Research, Vice president, Head of Biologics Discovery Jinming Gu, Sunshine Guojian Pharmaceutical, Vice President, R&D Kedan Lin, Biosion, Inc., Chief Development Officer (CDO)	15:00–15:20 Presentation: Global Trends in Bispecific/Multispecific Innovative Drugs Speaker: Shuona Yuan, PharmaCube, Senior Researcher 15:20–16:20 Panel Discussion: Clinical Translation Perspective – End-to-End Strategies for Antibody Drug Development from Clinical Trials to Market Access Moderator: Zhuli Wu, ImmuneOnco Biopharmaceuticals, CMO Panelists: Xinghua Hou, Huiyu Pharmaceuticals, CMO Jinjin Liang, Mabworks Biotechnology, CMO Wang Cong, MEDx, SVP of Research Antibody Combination Therapies 16:20–16:40 Presentation: Dose Optimization Across the Full Drug Lifecycle Speaker: Naihao Chen, Pfizer, VP of Clinical Pharmacology 16:40–17:00 Presentation: Dual Immunotherapy Combinations 17:00–17:20 Presentation: Bispecific Antibody Combinations 17:20–17:40 Q&A / Discussion	
			Back to Contents 23

BIOCHINA2026 In Vivo CAR-T Innovation Forum			BIOCHINA 2026 Stem Cell Drug Innovative Development Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	CMC & Delivery 09:00–10:00 Panel Discussion: Non-Clinical and CMC Considerations from IND Filing Moderator: Eric Xu, TCRCure, VP of MFG Panelists: Min Wang, PersonGen, VP Qinbin Wu, OBiO Technology, Deputy General Manager & CQO In Vivo CAR-T Delivery 10:00–10:20 Presentation: In Vivo CAR-T Delivery Based on mRNA-LNP Platform: Technology and Clinical Applications Speaker: Xiangrong Song, Ph.D., WestGene Biopharma, CEO & Scientific Co-founder 10:20–10:40 Presentation: In vivo mRNA-encoded immune cell engagers Speaker: Wei Xu, METiS Pharmaceuticals, CSO 10:40–11:00 Presentation: Targeted Delivery Strategies for mRNA CAR-X Therapy Speaker: Liyan Feng, Rhegen Biotech, Director of R&D	iPSC Development Session 09:00–09:20 Presentation: Cell Therapy for Parkinson’s Disease: Clinical Efficacy Validation and Global Progress of Next-Generation Therapies Speaker: Binyan Lu, Regen Therapeutics, VP, Product Projects 09:20–09:40 Presentation: Development and Clinical Translation of Pluripotent Stem Cells in Heart Failure Speaker: Yongsheng Xu, HELP Therapeutics, Co-Founder & CTO 09:40–10:00 Presentation: Clinical Progress of iPSC-Derived Endothelial Progenitor Cell Injections for Ischemic Vascular Diseases Speaker: Huiyuan Zhang, Allife Medical Science and Technology Co., Ltd., Senior Quality Director 10:00–10:20 Presentation: Clinical Development and International Strategy of Human iPSC-Derived Neural Progenitor Cell Injection Speaker: Jing Fan, Hopstem Bioengineering Co.,Ltd, Founder & CEO 10:20–10:40 Presentation: TBC Speaker: Fangfang Zhu, HemaCell Biotechnology Inc., CEO 10:40–11:00 Presentation: TBC Speaker: Xi Yan, Wiseheart MedVal, Vice President
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Clinical Development 12:00–13:00 Panel Discussion: Core Technology Routes and Clinical Strategies at the IIT Stage Panelists: Zhuoxiao Cao, Simnova Biotech, CEO Kaikai Shi, DeliNova Therapeutics, Founder & CEO Cheng Qian, Precision Biotech, Chairman & CSO Ting He, IMUNOPHARM Technology Co., Ltd., CEO 13:00–13:20 Presentation: Future Directions and Research Trends of Cell Therapy from a Regulatory Perspective Speaker: Jinghua Zhao, Fosun Kairos, CMO 13:20–13:40 Presentation: In Vivo CAR-T Tumor Therapy and Latest Clinical Progress (Tentative) Speaker: Cheng Qian, Precision Biotech, Chairman & CSO 13:40–14:00 Presentation: Anticipating and Managing Safety of In Vivo CAR-T	Process & Quality 12:00–12:20 Presentation: Selection of Vectors and Process Development for In Vivo Cell Therapy Speaker: Min Wang, PersonGen, VP 12:20–13:00 Panel Discussion: In Vivo CAR-T Manufacturing Process Challenges 13:00–14:00 Zhuhai Jinwan Special session	12:00–14:00 Stem Cell Processes and Manufacturing Session 12:00–12:20 Presentation: Development Strategies and Key Challenges of Pluripotent Stem Cell Product Processes Speaker: Alex Wu, Unixell Biotech, CMC sVP 12:20–12:40 Presentation: Establishment of Release Testing Systems for Stem Cell Therapy Products Speaker: Zhihui Bai, Shanghai East Hospital, Deputy Director of GMP Laboratory & Director of Quality Control Department 12:40–13:00 Presentation: TBC 13:00–14:00 Panel Discussion: Innovative Practices and Future Trends in Scalable Stem Cell Manufacturing Speaker: Alex Wu, Unixell Biotech, CMC sVP
14:00-15:00	Networking & Events	Networking & Events	14:00–16:00 MSC Development Session 14:00–14:20 Presentation: Technological and Clinical Breakthroughs of iPSC-Derived MSC Products Speaker: Chengyou Dong, Nuwacell Biotech Co., Ltd., GM Assistant 14:20–14:40 Presentation: Clinical Progress and New Global Development Pathways of Stem Cell Therapy for Acute Ischemic Stroke Speaker: Yingchun Jiang, Wingor Biotechnology, VP, Technology 14:40–15:00 Presentation: Latest Clinical Progress of MSC Therapy for Liver Cirrhosis Speaker: Dr. Chen Zheng, Zhejiang Quansheng Biotechnology Co., Ltd., CTO 15:00–15:20 Presentation: Clinical Exploration of MSC Therapy for Liver Failure Speaker: Yi Tan, Qilu Cell Therapy, VP and R&D Director 15:20–16:00 Panel Discussion: Opportunities and Challenges in MSC Drug Development under the “Rule 818” Moderator: Yi Tan, Qilu Cell Therapy, VP and R&D Director Panelists: Dr. Chen Zheng, Zhejiang Quansheng Biotechnology Co., Ltd., CTO Jing Fan, Hopstem Bioengineering Co.,Ltd, Founder & CEO Yingchun Jiang, Wingor Biotechnology, VP, Technology
15:00-18:00	Innovative R&D 15:00–16:00 Panel Discussion: In Vivo CAR-T R&D Progress and Development Prospects Panelists: Lianjun Shen, GRACELL, SVP Xiaowen He, Origincell Therapeutics, CSO Xueliang Yu, Starna Therapeutics, Vice President Bo Pei, Imviva Biotech, VP Fengtao You, PersonGen BioTherapeutics(Suzhou) Co.,Ltd., Director Innovative drug research Institute 16:00–17:00 In Vivo CAR-T Development — LVV vs. LNP, Who Leads the Way Planner: Feifei Qi, Immunopharm Technology Co., Ltd., Co-Founder & CTO 16:00–16:05 Opening Briefing 16:05–16:30 Presentation: Breakthroughs in Lentiviral Vector In Vivo CAR Technology Speaker: Lin Yang, PersonGen BioTherapeutics (Suzhou) Ltd., Co-Founder & Chairman & CEO 16:30–16:55 Presentation: In Vivo CAR-T Development Based on Circular RNA Speaker: Dr. Yun Yang, CirCode Biomed Co-Founder, Chairman & CTO 16:55–17:00 Q&A 17:00–17:20 Presentation: Engineering In Vivo CAR-T: Key Challenges and Frontier Progress Speaker: Nan Xu, Unicar-Therapy Bio-medicine, VP R&D 17:20–17:40 Presentation: In Vivo TCR-T R&D Speaker: Shi Zhong, Chief Scientist, PhD 17:40–18:00 Presentation: TBC Speaker: Tingting Wang, Lion TCR, COO & CMO	<div> BIOCHINA 2026 Stem Cell Drug Innovation Forum </div> Stem Cell Industry Policy & Translational Practice 15:00–15:20 Opening Presentation Speaker: Shaorong Gao, Tongji University, Distinguished Professor & Dean, School of Life Sciences & Technology & Academician, Chinese Academy of Sciences 15:20–15:40 Presentation: Lecheng Pilot Project 15:40–16:00 Presentation: Regulatory Policies 16:00–16:20 Presentation: Design of Phase III Clinical Trial of MSC for Knee Osteoarthritis (Tentative) Speaker: Liang Xu, ElpasBio Holdings, VP, CMO & CSO 16:20–16:40 Presentation: Drug Development for Neurological Disorders Speaker: Xiang Li, Xellsmart, CEO 16:40–17:00 Presentation: Latest Progress in Gene-Modified MSC Therapy for Type 2 Diabetes 17:00–18:00 Panel Discussion: Intersection of Technology, Clinical Practice, and Regulation — How to Facilitate the Industrialization of Stem Cell Innovative Drugs Panelists: Yu Zhang, VCANBIO Cell & Gene Engineering Corp., Ltd., Deputy General Manager Lanlin Wu, UniXell Biotechnology, CEO	

BIOCHINA2026 Exosome Innovative Development Forum		BIOCHINA 2026Cell Therapy Innovative Development Forum		BIOCHINA2026 Gene Therapy Innovative Development Forum	
Date	March 12th	March 13th		March 14th	
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Future Manufacturing 09:00-09:40 Panel discussion: Choices and Considerations for Future Commercial Manufacturing Moderator: Ivan Lin, JW Therapeutics Ltd., Head of Manufacturing/Head of MSAT&ATS Panelists: Wenshi Wang, FOSUNKAIRO'S, SVP Binghe Tan, BRL Medicine Inc., Parter & CTO Dr. Ruina Shi, Beijing Immunopharm Technology Co., Ltd., VP Pan Dai, 百思飞, Executive Director & General Manager 09:00-09:40 Presentation: Manufacturing of Allogeneic Human Immune Cells for Solid Tumor Immunotherapy Speaker: Andy Tan, Bioprocessing Technology Institute, A*STAR, Principal Scientist and Group Leader Innovation in Future Cell Therapy Manufacturing Planner: Ivan Lin, JW Therapeutics Ltd., Head of Manufacturing/Head of MSAT&ATS 10:00-10:20 Presentation: The Future of Bedside Cell Therapy Preparation under China's New Regulations: International Trends and Accessibility Breakthroughs Speaker: Ziqiu Guan, Miltenyi Biotec, Head of Regulatory Affairs & Clinical Expansion, China 10:20-10:40 Presentation: Fast CAR-T Speaker: Gracell Biotechnologies 10:40-11:00 Presentation: Considerations for CMC Global Expansion		Opening Panel discussion 09:00-09:40 Panel discussion: Impact of New Biomedical Technology Regulations on the Gene Therapy Field Panelists: Wei Guo, China Pharmaceutical University, Professor, School of Excellence in Biopharmaceutical Engineering Kanglian Zhang, Yuansong Biotechnology, General Manager Dr. Binlei Liu, Binhui Biopharmaceutical, Founder, Chairman & General Manager Yuanyuan Xu, Cure Genetics, CEO Technology and Clinical Innovation 09:40-10:00 Presentation: Clinical Translation of Gene Therapies for Neural Regeneration Speaker: Yuchen Chen, NeuExcell Therapeutics, VP, R&D 10:00-10:20 Presentation: Clinical Progress of In Situ Neuronal Regeneration Therapy for Parkinson's Disease Speaker: Dr. Jingmin Zhou, Genemagic Bio, Co-Founder & CEO 10:20-10:40 Presentation: Innovative Telomere-Targeted Gene Therapy for Heart Failure: Clinical Study Speaker: Yangyang Liu, Shanghai Juvensis Therapeutics Biotechnology, Co-Founder & Clinical Lead 10:40-11:00 Presentation: Clinical Data of Oncolytic Virus OH2 for Cold Tumors and Reversing Drug Resistance Speaker: Hanming Wang, Binhui Biopharmaceutical Co. Ltd, VP	
11:00-12:00	Lunch & Networking	Lunch & Networking		Lunch & Networking	
12:00-14:00	Technological Innovation and Clinical Translation Planner: Libo Zhao, Echo Biotech Co., Ltd., CTO & Co-Founder 12:00-13:00 Panel discussion: Clinical Challenges and Breakthroughs in Exosome Therapy Moderator: Libo Zhao, Echo Biotech Co., Ltd, Co-Founder & CTO Panelists: Haonan Xing, National Center for Nanoscience and Technology Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, Dept. Ophthalmology Hang Hubert Yin, Tsinghua University, Beijing, Professor of Pharmaceutical Sciences Linzhao Cheng, USTC, Chair Professor & Dean, School of Life Sciences and Medicine & Tenured Professor, Johns Hopkins University 13:00-13:20 Presentation: Exploratory Study of Engineered Extracellular Vesicle Therapy for Ophthalmic Diseases Speaker: Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, Dept. Ophthalmology 13:20-13:40 Presentation: Human Stem Cells and Engineered-Derived EVs Speaker: Linzhao Cheng, USTC, Chair Professor & Dean, School of Life Sciences and Medicine & Tenured Professor, Johns Hopkins University 13:40-14:00 Presentation: Novel High-Efficiency Delivery Strategies Speaker: Hang Hubert Yin, Tsinghua University, Beijing, Professor of Pharmaceutical Sciences	Immunotherapy Drug Development 12:00-12:20 Presentation: Synthetic NK Cells and Anti-Aging Immunotherapy Speaker: Zhigang Tian, Chinese Academy of Engineering, Academician 12:20-12:40 Presentation: Rapid Translation Strategies and Practices for Mature CAR-T Platforms Speaker: Bing Du, East China Normal University, Professor: BRL Medicine Inc., Co-Founder 12:40-13:00 Presentation: CAR-NK Therapy for Relapsed/Refractory SLE Speaker: Ming Sun, Shenzhen Rui Therapeutics Co., Ltd., CSO 13:00-14:00 Panel discussion: Expansion of Cell Therapy Indications and Clinical Development Strategies Panelists: Lun Zeng, MBA, XLifeSc, CEO Tongcun Zhang, Bio-Raid Biotechnology, Founder Liqun Wang, Neukio Biotherapeutics, CEO Zhao Wu, Innovative Cellular Therapeutics, Co-Founder & President Zhinan Yin, Jide Kongming Biomedical, Professor & Dean, Founder & Chairman		Indication Development & Clinical Breakthroughs – Rare Diseases 12:00-12:20 Presentation: Clinical Progress and Accessibility Breakthroughs of AAV Gene Therapy for Retinal Diseases Speaker: Amy Chen, Chengdu Genevector Biotechnology Co., Ltd., VP 12:20-13:00 Panel discussion: Gene Therapy Development Strategies for Rare Diseases Panelists: Dr. Yixiong Chen, Shanghai Lingyi Biotech Co., Ltd., CSO Amy Chen, Chengdu Genevector Biotechnology Co., Ltd., VP Xiaoyan Dong, GeneCradle, Co-Founder Guiyi Zhang, Gritgen Therapeutics, CTO Indication Development & Clinical Breakthroughs – Ophthalmology 13:00-13:20 Presentation: Innovative AAV Vectors Targeting Heart/Muscle and Development of Long-Acting Heart Failure Gene Therapy Speaker: Lei Zhao, Cure Genetics Co.Ltd., Executive Director 13:20-14:00 Panel discussion: Gene Therapy Development Strategies for Ophthalmic Diseases Panelists: Dr. Kai Wu, UgeneX Therapeutics, President Zhenhua Wu, Exegensis Bio Inc., Founder & CEO Sikai Ling, Bendao Gene, VP of R&D Indication Development & Clinical Breakthroughs – Chronic Diseases 14:00-14:20 Presentation: Applications of Innovative Base Editing Technologies in Metabolic Diseases Speaker: Susan Mou, CorrectSequence Therapeutics, CEO 14:20-15:00 Gene Therapy Development Strategies for Chronic Diseases Panelists: Yang Hu, Lumiere Therapeutics (Suzhou)Co., LTD, CEO Robin Tan, Refreshgene Therapeutics, Co-Founder & CTO Susan Mou, Ph.D., CorrectSequence Therapeutics, CEO Qing Lin, Lingyi Biotech, CEO CMC and Regulatory Submission 15:20-15:40 Coordinated Development of Biomedical Technologies and Drug Submission Speaker: Ping Li, Exegensis Bio, Senior Director, Regulatory 15:40-16:20 Panel discussion: IIT/Clinical Perspectives on CMC Development Requirements Panelists: Herman He, SineuGene Therapeutics Co., Ltd., CMC Head Xikui Gong, Fosun Pharma, Director, CMC Jun Xiao, Shanghai Vitalgen BioPharma, Quality VP Hongxing Wang, Euhearing Therapeutics, CTO Xudong Zhu, Kanglin Biotech, Quality Director	
14:00-15:00	Networking & Events	Networking & Events		Networking & Events	
15:00-18:00	Executive Panel Discussion 15:00-15:40 Panel discussion: Innovative Breakthroughs in Exosome Development Panelists: Haoran Wang, Newland Biotechnology, CEO Xiaohu Ge, Tianjin Exosome Technology Co., Ltd., Chairman Dr. Grace Zhou, ImmVira Pharma, CEO Guanyi Kong, Echo Biotech, CEO Exosome Delivery and Carrier Research 15:40-16:00 Presentation: Engineering Exosomes on the OVPENS Platform: Innovative R&D and Applications Speaker: Xiaoging Chen, ImmVira Bioscience, CSO 16:00-16:20 Presentation: Engineered Exosomes Crossing the Blood–Brain Barrier: A New Paradigm for CNS Nucleic Acid Drug Delivery Speaker: Tinghe Wu, Cohen-Ris Biopharm, Founder & CEO 16:20-16:40 Presentation: Smart Targeted Drug Delivery Platform Exosome Clinical Translation Research 16:40-17:00 Presentation: Tumor Combination Therapy 17:00-17:20 Presentation: Neurodegenerative Diseases Exosome Large-Scale Production Process Optimization 17:20-17:40 Presentation: Separation and Purification 17:40-18:00 Presentation: Large-Scale Production Optimization Strategies	Solid Tumor Drug Development 15:00-15:20 Presentation: Development of the World's First Autologous CAR-T Therapy Speaker: Zonghai Li, CARsgen, Founder & CEO 15:20-15:40 Presentation: gdT Cells: A New Frontier in Solid Tumor Cell Therapy Speaker: Zhinan Yin, Jide Kongming Biomedical, Professor & Dean, Founder & Chairman 15:40-16:00 Presentation: Clinical Progress of CoupledCAR Platform Technology for Advanced Solid Tumors Speaker: Zhao Wu, Innovative Cellular Therapeutics, Co-Founder & President 16:00-16:20 Presentation: Advances in Cell Therapy for Hepatocellular Carcinoma Speaker: XiaoWu Huang, Zhongshan Hospital, Fudan University, Director of the Biotherapy Center, Professor and Chief Physician of Hepatobiliary Oncology and Liver Transplantation 16:20-16:40 Presentation: Ultra-Low Dose Metabolism-Enhanced Cell Therapy Speaker: Dudu Tong, Leman Biotech, Executive Director 16:40-17:00 Presentation: TCR-T Development for Solid Tumors Speaker: Kai Zhan, XLifeSc, General Manager Assistant, BD Director & Senior Scientist 17:00-17:20 Presentation: CAR-NK Development for Solid Tumors Speaker: Xiangfeng He, Inber Biotech, CMO 17:20-17:40 Presentation: Exploring Curative Strategies for Solid Tumors Speaker: Meijia Yang, Ph.D., NaviGen Bio, Founder and Chairman 17:40-18:00 Presentation: TBC Speaker: Tianhong Xu, Base Therapeutics, Founder & CEO		<div>Back to Contents</div> <div>25</div>	

BIOCHINA2026 Biomanufacturing Innovative Development Forum			
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	Agricultural Innovation 09:00–09:20 Presentation: Straw-Based Biomanufacturing to Drive Agricultural Innovation Speaker: Cheng Li, PolyView Biotechnology, Co-Founder & CTO 09:20–09:40 Presentation: Breaking the Production Bottleneck in Cell Factories: Bacillus Lipopeptides Revitalizing Industries and Nature Speaker: Yukang Xie, Ph.D., SYN Biotechnology, Co-Chief Scientist 09:40–10:00 Presentation: Intelligent Production and Industrialization of Microbial Proteins from Straw-Based Feedstocks Speaker: Zhenyun Liu, Yixi Biotech, Founder & CEO 10:00–10:20 Presentation: Bio-Substitute of White Mustard Alkaloid: From Plant Extraction to Yeast-Based Synthesis Speaker: Yan Feng, Shanghai Jiao Tong University, Distinguished Professor & Deputy Director, State Key Laboratory of Microbial Metabolism 10:20–11:00 Panel Discussion: Agricultural Innovation through Biomanufacturing Panelists: Cheng Li, PolyView Biotechnology, Co-Founder & CTO Yukang Xie, Ph.D., SYN Biotechnology, Co-Chief Scientist	AI + Biomanufacturing 09:00–10:00 Panel Discussion: The Future Transformation of AI + Biomanufacturing 10:00–10:20 Presentation: Construction of High-Expression Strains Using AI Speaker: Yongliang Zhu, Pryson Technology, Chairman & CSO 10:20–10:40 Presentation: TBC Speaker: Zishuo Zeng, Synerces Biosciences, R&D Director & Bioinformatics Scientist 10:40–11:00 Presentation: Intelligent Control of Bioreactor Processes
	10:00-10:30 Presentation: Biomanufacturing Driving a Revolution in Pharmaceutical Development 10:30-11:00 Presentation: Chassis-Free In Vitro Biotransformation (ivBT) Enabling Dimensionality-Reduced Biomanufacturing Speaker: Yiheng Zhang, Tianjin Institute of Industrial Biotechnology, CAS, Director, Center for In Vitro Synthetic Biology & National Key Lab of Low-Carbon Synthetic Biology		
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Food Development 12:00-12:20 Presentation: Compliance and Standardization of New Food Ingredients from Synthetic Biology Speaker: Ming Liu, China National Research Institute of Food & Fermentation Industries, Deputy Director, Standards & Digitalization R&D Department 12:20-12:40 Presentation: Creation and Applications of Next-Generation Microbial Proteins Speaker: Xianzhi Jiang, MoonBiotech, Founder & CEO 12:40-13:00 Presentation: Development of Bio-Cell Factory for Food–Medicine Homology High-Activity Compounds (AKG, Ganoderic Acids, Ganoderma Polysaccharides, etc.) Speaker: Yifa Yu, Nanning Harworld Biological Technology, Executive Vice General Manager & Director, R&D 13:00-13:20 Presentation: Research and Development of ZhiYi Bio's Next-Generation Probiotic AKK-AM06 Speaker: Yangyang Liu, Zhiyi Biotechnology, Deputy General Manager & Co-Founder 13:20-13:40 Presentation: Smart Engineering of Animal Cells for Cultivated Meat Applications Speaker: Andy Tan, Bioprocessing Technology Institute, A*STAR, Principal Scientist and Group Leader 13:40-14:00 Presentation: Safety Evaluation Technologies for Genetically Modified Microorganisms and Their Application in Novel Food Approval Speaker: Lei Zhai, China National Research Institute of Food & Fermentation Industries, Director, Biotechnology R&D Department	Agricultural Innovation 12:00–14:00 Agriculture Innovation Session 12:00–12:20 Presentation: Enhancing Agricultural Productivity through the Microbiome 12:20–12:40 Presentation: Development of Novel Biofertilizers and Animal Feed 12:40–13:00 Presentation: Cultivation of Functional Crops 13:00–13:20 Presentation: Development of Biopesticides and Formulations 13:20–14:00 Panel Discussion: Empowering Agricultural Innovation with Synthetic Biology	AI + Biomanufacturing 12:00–12:20 Presentation: AI-Designed Metabolic Pathways for Greener Cosmetic Ingredients 12:20–12:40 Presentation: AI-Assisted Recombinant Collagen Molecular Design 12:40–13:00 Presentation: AI-Driven Design of Biocatalytic Enzymes Enzyme & Metabolic Engineering 13:00–13:20 Presentation: NMR-Guided Directed Evolution of Enzymes Speaker: Lichun He, Ph.D., Chinese Academy of Sciences (CAS), Professor 13:20–13:40 Presentation: Biosynthesis of Non-Natural Compounds Driven by Enzyme Engineering Speaker: Lipo Zhang, Westlake University, Distinguished Researcher 13:40–14:00 Presentation: Spatial Capability Design of Enzymes and Biosynthesis Speaker: Zhoutong Sun, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Researcher Cell Factories & Industrial Strain Industrialization 14:00–14:20 Presentation: Construction of Efficient Microbial Cell Factories Based on Synthetic Biology and Their Industrial Applications Speaker: Zhiming Rao, Jiangnan University, Associate Dean, School of Biochemical Engineering 14:20–14:40 Presentation: Halomonas Chassis Design and Its Applications in Biomanufacturing Speaker: Jianwen Ye, South China University of Technology, Professor, School of Biological Science and Engineering 14:40–15:00 Presentation: Reprogramming and Optimization of High-Yield Industrial Strains for Stable Production and Industrial Applications Speaker: Shihui Yang, Wuhan Ruijiakang Biotech, Professor, Hubei University & Founder, Wuhan Ruijiakang Biotech 15:00–16:00 Panel Discussion: Accelerating Biomanufacturing Industry Development through Research Panelist: Shihui Yang, Wuhan Ruijiakang Biotech, Professor, Hubei University & Founder, Wuhan Ruijiakang Biotech
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Food Development 15:00-15:20 Presentation: TBC Speaker: Jingya Zhao, Zeno Technology, Deputy General Manager & COO 15:20-15:40 Presentation: Production Strategies from Non-Food Biomass to Microbial Proteins Speaker: Fengli Zhang, Shanghai Jiao Tong University, Associate Researcher, School of Life Science and Technology 15:40-16:30 Panel Discussion: Opportunities in Biomanufactured Food from Different Perspectives Panelist: Ying Zhang, SDIC Convergence Investment Management Co., Ltd., Investment Director Yifa Yu, Harworld Biotech, EVP & R&D Director Fermentation Track 16:30–16:50 Presentation: Customized Construction of Novel Fermentation Platforms and Industrialization Enablement 16:50–17:10 Presentation: Scale-Up Technologies and Industrialization Case Studies of 10,000-Ton Industrial Fermenters 17:10–18:00 Panel Discussion: Collaborative Pathways for Novel Fermentation Platforms Across Academia, Industry, and Capital — Technology Licensing, Production Line Implementation, and Multi-Party Win-Win Panelist: Lei Zhai, China National Research Institute of Food & Fermentation Industries, Director, Biotechnology R&D Department	Aesthetic Biotechnology Planner: R.X. Lee, Highlight Capital, Director 15:00–18:00 Cosmeceuticals and Biomanufacturing Session 15:20–15:40 Presentation: TBC Speaker: Ruiyan Wang, Huaxi Biotech, General Manager, Raw Material R&D Center 15:40–16:00 Presentation: New Cosmetic Ingredients – Single-Cell Microalgae Extracellular Vesicles Speaker: Yujiao Qu, Protoga Biotech, Chief Biotechnology Officer & Deputy Director, Microalgae Biosynthesis R&D Center, Tsinghua Shenzhen International Graduate School 16:00–16:20 Presentation: TBC Speaker: Wenge Wang, 江太生物, Chairman & CEO 16:20–16:40 Presentation: TBC Speaker: Zhiquan Yan, 深圳微智生物, CEO 16:40–17:00 Presentation: Application of Biosynthetic Regenerative Microspheres in Cosmeceuticals 17:00–17:20 Presentation: Development of Long-Chain Recombinant Collagen Products 17:20–18:00 Panel Discussion: Process Innovation and Product Development Panelist: R.X. Lee, HighLight Capital, Director	
<div>Back to Contents</div> <div>26</div>			

BIOCHINA 2026 Roadshow				
Date	March 12th		March 13th	March 14th
9:00-11:00			In Vivo CAR-T Roadshow Special Guests: Ning Li, Gaorong Ventures, ED Karen Liu, Ph.D., 3E Bioventures Capital, Founding Partner Xiaoxiao Peng, InnoPinnacle Fund, Managing Director Project: In Vivo CAR-T Based on Antibody Non-Chemical Site-Specific Conjugated LNP Technology Funding Stage: Angel	Artificial Intelligence Roadshow Special Guests: Yuqin Zhang, Proxima Capital, Vice Director Scientific Research Roadshow Special Guests: Liqiong Pang, CASVC, ED I. Small-Molecule Drug Conjugate (SMDC) Delivery / Oral Platform and Innovative Drug Development II. Original Dual-Pathway Innovative Drug Development for Coronary Heart Disease III. Cytokine Prodrug Development for Cancer Immunotherapy IV. Dual-Mechanism PCC Molecules Against Deep-Seated Fungal Infections
11:00-12:00	Lunch & Networking		Lunch & Networking	Lunch & Networking
12:00-14:00	Innovative Drug Roadshow Special Guests: Dr. Vince Deng, Med-Fine Capital, Partner Daniel Ying, OrbiMed, Executive Director Tingzhi Qian, Prosperico Ventures, Funding Partner Hua Yi, SDIC Capital, Director & General Manager I. Project: Nanobody ADC Targeting GPC3 (NDC) Funding Stage: Angel + Pre-A II. Project: Innovative Organ-Targeted Oligonucleotide Therapeutics Funding Stage: Angel III. Project: FIC Small-Molecule Autophagy and Apoptosis Inducers for Alzheimer's Disease, Chronic Cancer Pain, and Gastric Cancer Funding Stage: Angel IV. Project: Discovery and Clinical Development of α-Radionuclide ^211At-Labeled Targeted Radiopharmaceuticals for Cancer Therapy Funding Stage: Series A V. Project: Gene Therapy for Heart Failure Funding Stage: Pre-A VI. Project: Global Innovative Small-Molecule Immuno-Oncology Agonists Funding Stage: Pre-A VII. Project: Novel Bispecific ADC Molecule for Glioma Treatment Funding Stage: Pre-A VIII. Project: "Lightning Pathway" Program — Rapid Engine for CGT Commercialization in the First Golden Year Following the Implementation of Regulation 818 Funding Stage: Angel		BD Partnership Roadshow	Biomanufacturing Roadshow Special Guests I. Project: Non-Animal-Derived Single-Cell Recombinant Exosome Technology and Its Intelligent Manufacturing & Industrialization Platform Funding Stage: A+
14:00-15:00	Networking & Events		Networking & Events	
15:00-18:00	Innovative Technologies & Therapies Roadshow Special Guests I. Project: Sub-Centimeter Liver Cancer (≤10 mm) MRI Early Screening Technology (Nayouming®) Funding Stage: Angel		15:00-16:30 Korea-Focused Projects Roadshow Special Guests: Marc Appel, Pacific Bridge, Managing Partner Hugh Xu Huang, Pfizer, Discovery Network–Director & External Science Lead China	<div>Back to Contents</div> <div>27</div>

BIOCHINA 2026 Brainstorming

Date	March 12th	March 13th	March 14th
9:00-11:00	Exhibition Hall Closed During Opening Ceremony	Cell Therapy R&D 09:00-10:00 Opportunities and Key R&D Points for CGT Therapies under Regulation 818 Speaker: Yansheng Dong, SAFE Pharmaceutical, SVP Practical Key Points in Clinical Research Data Management and Audit 10:00-11:00 Presentation: Internationalization of Clinical Development — Case Studies in Autoimmune and Metabolic Diseases Speakers: Heng Su, ICON, Head of Business, Greater China Wanni Zhao, ICON, Director of Business, Central Laboratory	Cell Therapy CMC and Regulatory Focus 09:00-10:00 Panel Discussion: Challenges in Differentiated Process Development for Autologous and Allogeneic Cell Therapies <ul style="list-style-type: none"> • Key Differences in Process Design and Development • Commercialization and Cost Considerations Panelist: Fenghua Lv, Base Therapeutics (Shanghai) Co, Ltd., Senior Director of CMC and Head of Quality 10:00-10:45 Presentation: Low-Cost Process Solutions for Cell Therapy Speaker: Yanzhou Huang, SCG, Vice President of Process Development <ul style="list-style-type: none"> • Changes in the Technical Framework • Replacement and Upgrade of Existing Solutions 10:45-11:00 Q&A
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	Peptide Session 12:00-13:00 Cyclic Peptide Development <ul style="list-style-type: none"> • Molecular Design, Screening, Synthesis, Safety • Application Potential: Pharmaceutical, Cosmetic 13:00-13:30 Presentation: Advancing Precision Oncology with Next-Generation Peptide Cancer Vaccines Speaker: Asma Khanniche, Anda Biology, R&D director 13:30-14:00 Presentation: GLP-1 Multi-Target Approaches and New Indication Expansion Speaker: Li Zhang, Pyrovita Therapeutics, CTO	Conjugated Drugs Focus 12:00-13:00 PDC Conjugates 13:00-14:00 AOC: Antibody-Oligonucleotide Conjugates Speaker: Yanming Shen, Porton Pharma Solutions Ltd., Director of R&D, Biologics Drug Development & Manufacturing Center	Cell Therapy Quality Session 12:00-13:00 Panel Discussion: Challenges and Innovative Practices in Cell Therapy Quality Control <ul style="list-style-type: none"> • Release Testing for Live Cell Products • Residuals in Viral Vector Processes • Potency Assay Methods Panelists: Mingyang Gu, Nanjing AcrolImmune Biopharmaceutical Co. Ltd, General Manager Assistant Meiling Wang, PRECISION BIOTECH, QC Lead Rui Li, Neukio Biotherapeutics, Senior Director of Quality 13:00-14:00 Panel Discussion: Global Regulatory Approval and Lifecycle Management of Cell Therapy Products <ul style="list-style-type: none"> • Strategies and Post-Market Changes Across Different Regulatory Systems (China, US, EU) • Indication Expansion and Real-World Data Applications Panelists: Shuping Fang, Simcere, Director Yingyi Shu, Shanghai Protocell Medical Technology Co., Ltd., Senior Registration Director
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Antibody Session 15:00-16:00 Panel Discussion: Quality Analysis and Quality Management <ul style="list-style-type: none"> • Accelerating Development of Biologics Quality Attribute Analytical Methods Using New Technologies • Case Studies on Quality Management Panelists: Qingmin Wang, Qilu Pharmaceutical, Executive Director, Biotech Development Institute DaiDi Hu, CSPC Megalith Biopharmaceutical, Head of Quality Department 16:00-17:00 Presentation: Insights from Onsite Inspections of Overseas Manufacturing of Imported Drugs Speaker: Terry Lu, Harbour BioMed, Quality Director	Conjugated Drugs Focus 15:00-15:30 Presentation: ADC Process Development: Key CMC Pathways from Clinical to Commercialization Speaker: Zhiping Yao, Haoyuan Chemexpress, CTO 15:30-16:00 Presentation: Key Considerations in Small-Molecule ADC CMC Speaker: Xianglin Zhao, Haoyuan Chemexpress, Deputy General Manager, Innovative Drug Services Division 16:00-17:00 RDC-Radionuclide Conjugated Drugs 17:00-18:00 Commercial-Scale ADC Manufacturing <ul style="list-style-type: none"> • ADC Workshop Protection (Use of Disposable Clean Suits and PPE) • Small-Molecule Inactivation (Inactivation of Small-Molecule Toxins in ADC Production) • Waste Management (Full-Process Classification and Compliance) • ADC Toxin Handling (Risk Control Throughout Production Process) 	Stem Cell Session 14:00-15:00 Indication Expansion of Stem Cell Therapies: From Rare Diseases to Common Diseases

BIOCHINA 2026 Brainstorming			
Date	March 12th	March 13th	March 14th
9:00-11:00		Radiopharmaceuticals Session 09:00–09:45 Presentation: Overview of Radiopharmaceutical Regulations in China Speaker: Shaofeng Zhang, BoomRay Pharmaceutical Co., Ltd., QA Assistant Director 09:45–10:00 Q&A Session 10:00–11:00 Quark Pharma Special Focus Panel Discussion: Innovative Translational Pathways and Global Industrial Strategy in Radiopharmaceutical Development <ul style="list-style-type: none"> Breaking Traditional Target Limitations: Development Pathways and Clinical Application of Emerging Targets Going Global: Market, Collaboration, and Supply Chain Challenges in Radiopharmaceuticals 	Antibody R&D Session Innovative Approaches in Bispecific Antibody Molecular Design 09:00–09:20 Presentation: Development Progress and Considerations of Brain-Penetrant Antibodies Speaker: Dong Yang, 4B Technologies Investments, Director of R&D Autoimmune Diseases Session 10:00–10:20 Presentation: Autoimmune-Related Research
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	In Vivo CAR-T Session 12:00-13:00 Presentation: From Characterization to Scale-Up: Key Parameters and Quality Control of In Vivo CAR-T Manufacturing Speaker: Xin Wu, Levostar Life Sciences, Founder & CEO 13:00-14:00 Interview, In Vivo CAR Companion Diagnostics Moderator: Jianfei Zhang, Kaijie Conversion Medical, BD Director 13:00-13:05 Opening 13:05-13:30 Presentation: TBC Speaker: Fengtao You, PersonGen BioTherapeutics, Director Innovative Drug Research Institute 13:30-13:55 Presentation: TBC Speaker: Zhengguo Pang, Kaijie Conversion Medical, Senior Director 13:55-14:00 Q&A	Artificial Intelligence Session 12:00–13:00 Panel Discussion: Accelerating Early-Stage Scientific Discovery with AI – Case Studies Moderator: Yaxian Zhao, PhD in Neurophysiology, Host of the technology podcasts Panelist: Jue Wang, InSilico Medicine Cayman TopCo, VP of Business 13:00–14:00 Case Studies in AI and Engineering Automation	Small Molecule Innovation & Development Session 12:00–13:00 Clinical Translation Strategies 13:00–14:00 CMC and Manufacturing 14:00–15:00 PPQ: Process Performance Qualification
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	Immuno-Cell Therapy Session 15:00–16:00 Gene-Edited TIL Product Development Speaker: Dr. Aotian Xu, Huasaiboman Medical Cell Biology Co., Ltd., Senior R&D Director Cold Chain Logistics Session 16:00–17:00 Cold Chain Transportation for Biologics Speaker: Jianming He, Yingji Pharmaceutical, Regional Marketing Director Cell Therapy Manufacturing and Quality Control Session 17:00–18:00 Panel Discussion: From “Workshop” to “Smart Factory”: Scaling Up Cell Therapy Manufacturing <ul style="list-style-type: none"> Automation, Cost Reduction & Efficiency, and Product Quality Consistency Panelists: Liang Su, BRL Medicine, Manufacturing Director Shouliang Wu, Vcanbio Cell & Gene Engineering Corp., Ltd., Manager of Manufacturing Science & Technology Yusheng Qu, XLifeSc, Director of Cell Preparation	Organoids for Drug Development Tumor Organoids Session 15:00–15:20 Presentation: TBC 16:00–17:00 Organoids for Neurodegenerative Diseases 17:00–18:00 Organoids for Metabolic Diseases	
			Back to Contents
			29

BIOCHINA 2026 (11th Edition) Agenda						
	Time	Close-door Meeting	Main Stage 1	Main Stage 2	BIOCHINA Reception	BIOCHINA Activities
Mar12	09:00-10:00 10:00-11:00	/	BIOCHINA Awards: Annual Supplier Ceremony	/		
	11:00-12:00	Networking	BIOCHINA International Dialogue Moderator: Maxwell Kirkby, Huang and Kirkby Medical Consulting, CEO Mr. Alexandre Cérat, Consulate General of Canada in Shanghai, Deputy Consul General & Commercial Officer Sjord Dikkerboom, Netherlands Innovation Network, Officer for Innovation, Technology & Science	BIOCHINA Bio Festival Runway Show New Product Launches ProBio Technology Sunresin Duoning Biotech 百思飞 Pan Dai, 百思飞, Executive Director & General Manager	Procurement Lunch Meeting	
	12:00-13:00 13:00-14:00	Government & Regulatory Close-door Meeting	/	/		
	14:00-15:00	Networking	BIOCHINA Bio Festival Life Stories Lecture Hall Aimin Hui, EnCureGen Pharma, Founder, Chair & CEO Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, Dept. Ophthalmology	BIOCHINA International Supply & Procurement Dialogue Vladimir Popov, ROSBIOTECH & ESMAR Ltd., Professor & CEO	Open	March 12-13 BIOCHINA 2026 Annual Product Awards Voting
	15:00-16:00 16:00-17:00 17:00-18:00	Biomanufacturing Close-door Meeting Emerging Regions International Exchange Closed-Door Session	/	/		March 14 BIOCHINA 2026 Annual Product Awards Ceremony
	18:00-20:00					BIONIGHT Invitational Dinner
	09:00-10:00 10:00-11:00	Upstream International Expansion Close-door Meeting	/	/		
Mar13	11:00-12:00	Networking	BIOCHINA CEO Dialogue Panel Discussion: Our Drug Launch Journey in 2025 Ziye Sui, Lepu Biopharma Co., Ltd., CEO Yanjun Xu, Xuanzhu Biotech, Chairman Cheng Qian, Precision Biotech, Chairman & CSO	BIOCHINA Bio Festival Awards New Product Launches Incess: Eight-Channel Purification, Fast & Smart — Launch of the Inscinstech 8-Channel Fully Automated Protein Purification System Tao Zhang, Incess, Chromatography Product Manager Challenge IM Guiling Jia, Challenge IM, Founder & CEO	ExCell Bio Lunch Meeting	March 12-14 All-Day Activities BIOWALK: Exhibition Exploration & Check-In BIOCHINA Bio Festival Product Challenge BIOCHINA Bio Festival Charity Art Exhibition BIOCHINA Bio Festival Annual Moments Photo Exhibition BIOCHINA Bio Festival Curated Bacterial Culture Art Display BIOCHINA Bio Festival Tree of Life Wishing Activity
	12:00-13:00 13:00-14:00	PI Face-to-Face – Metabolism International Regulatory Closed-Door Meeting – Indonesia	/	/		
	14:00-15:00	Networking	BIOCHINA Upstream Dialogue Panel Discussion: Rebuilding Symbiosis: The "Partner" Era of International Innovation Ecosystems Moderator: Li Jia, Lang Sheng Investment, Partner Yan Gu, Crown Bioscience, CEO Dr. Jijie Gu, WuXi Biologics, CSO & President of Global Biologics Research Christian Schmidtgen, Bayer Pharmaceuticals, Head of R&D Finance, Resource & CRO Management	BIOCHINA CSO Dialogue Panel Discussion: A Scientist Who Doesn't Do BD Isn't a Good CSO – Maximizing Pipeline Value Through Endless Innovation Iterations Moderator: Yaxian Zhao, PhD in Neurophysiology, Host of the technology podcasts Dr. Yiping Rong , Harbour BioMed, CSO Jiaqiang Cai, Ph.D., MediLink Therapeutics, Co-Founder, Co-CEO & CSO	Sino-Dutch Life Sciences Delegation · Networking Reception	
	15:00-16:00 16:00-17:00 17:00-18:00	International Regulatory Meeting – Pakistan PI Face-to-Face – Metabolism PI Face-to-Face – CNS	/			
	18:00-20:00	Networking			Korea Night CSO & CMO Reception CTO Reception	
	09:00-10:00 10:00-11:00	/	/	/		
	11:00-12:00	Research Translation Close-door Meeting	BIOCHINA 2026 Annual Product Awards Ceremony BIOCHINA CTO Dialogue	BIOCHINA CMO Dialogue	Open	
Mar14	12:00-13:00 13:00-14:00 14:00-15:00	Moderator: Junhua Qiao, GeneScience Pharmaceutical, CTO			/	

Join us at BIOCHINA2026



▶▶▶ **BIOCHINA** ◀◀◀

Connecting Innovators, Enabling Bio-industry.
China's leading communication platform in Bio-industry



▶▶▶ **BioBD Group** ◀◀◀



▶▶▶ **BIOCHINA GCD Group** ◀◀◀
(Global Clinical Group)



▶▶▶ **WhatsApp Group** ◀◀◀